MOLECULAR GENETICS OF FLUOROQUINOLONE RESISTANCE AND THE STRUCTURES OF KEY PYRIMIDINE BIOSYNTHESIS PATHWAY ENZYMES FROM MYCOBACTERIUM TUBERCULOSIS by GHODE PRAMILA BABAN
i 
 
MOLECULAR GENETICS OF 
FLUOROQUINOLONE RESISTANCE AND THE 
STRUCTURES OF KEY PYRIMIDINE 





GHODE PRAMILA BABAN 
(M.Sc., University of Pune) 
 
 
A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
 
DEPARTMENT OF BIOLOGICAL SCIENCES 








I hereby declare that this thesis is my original work and it has been written by me 
in its entirety. I have duly acknowledged all the sources of information which 
have been used in the thesis.  














I wish to express my deepest gratitude to my supervisor at NITD, Dr. Pablo Bifani 
for his guidance in my PhD project and helping me develop my background in 
molecular genetics (Chapter 3). 
I would like to express my deepest gratitude to my supervisor at NUS, Prof. J. 
Sivaraman for his immense support, constant encouragement and guidance in 
structural biology that has made this thesis work (Chapters 4 and 5). 
I would like to acknowledge Novartis Institute for Tropical Diseases, Singapore, 
for sponsoring my PhD program at NUS. 
I would like to express my gratitude to Prof. Paul Herrling for not only giving me 
an opportunity to work at NITD but also for constant support and encouragement 
throughout my PhD tenure. 
I wish to express my gratitude to Prof. Srikant Datar for guiding me during the 
initiation of my research journey. 
I wish to thank, Patricia, for your emotional support, Meera, for transforming me 
with all your encouraging thoughts, be it science or life. I wish to thank my 
cheerful colleagues at NITD- Bee Huat, Boon Heng, Adeline, Vivian and Jessie, 
for their advice and help in the lab. A huge thanks to my friends at NITD- Pamela, 
Michelle, Vanessa, Hazel, Jessica, Vimala, Priya and Ponnu for all the fun-filled 
times and dinner outings. 
I wish to extend my thanks to my NUS colleagues, Jobi, Priyanka, Deepti, Digant 
and specially Sarath for the discussions and helping me in the work at NUS. A 
huge thanks to my friends at NUS- Pavithra, Pradeep, Bidhan and Tanusya for 
their care and for being there always. 
Finally, I express my deepest gratitude to my parents for their love, 
encouragement and blessings throughout. 
I thank God for the strength throughout. I dedicate this thesis to my late 
grandfather and my brother. 
iv 
 
TABLE OF CONTENTS 
Summary…………………………………………………………………………ix 
List of Figures…………………………………………………………………..xii 
List of Tables…………………………………………………………………....xv 
List of Abbreviations…………………………………………………………..xvi 
Publications…………………………………………………………………….xix 
Poster presentations…………………………………………………………….xx 
1 Introduction- Tuberculosis………………………………………………….1 
1.1   Tuberculosis: etiology and epidemiology……………………………….2 
1.2   Mycobacterium tuberculosis pathogenesis………………………………5 
1.3   Prevention of tuberculosis………………………………………………..7 
1.4   Diagnosis…………………………………………………………………7 
1.5   Treatment……………………………………………………………….12 
1.6   Drug resistance- Challenge in tuberculosis control…………………….15 
1.6.1 MDR, XDR and TDR……………………………………………16 
1.6.2 Fluoroquinolones for drug resistant TB………………………….19 
1.6.3 Molecular genetic basis of drug resistance………………………22 
1.7   Tuberculosis drug development- progress and strategies………………23 
1.7.1 Repurposing of drugs for TB treatment………………………….25 
1.7.2 Identification of novel targets in Mtb for drug design…………...26 




2 Material and Methods………………………………………………………..31 
2.1 Molecular genetics of fluoroquinolone resistance……………………….31 
2.1.1 Mycobacterial strains and culture conditions……………………31 
2.1.2 Fluoroquinolones………………………………………………...31 
2.1.3 Recovery of spontaneous mutants with fluoroquinolones……….32 
2.1.4 Sequence analysis of gyrA and gyrB……………………………..32 
2.1.5 Characterization of fluoroquinolone resistant mutants…………..34 
2.1.6 Mutant prevention concentration…………………….…………..35 
2.2 Structural basis of mapping the spontaneous mutations with 5FU in uracil 
phosphoribosyltransferase from Mycobacterium tuberculosis (MtUPRT)…..36 
2.2.1 Cloning expression and purification of MtUPRT………………..36 
2.2.2 Dynamic light scattering (DLS) of MtUPRT…………………….38 
2.2.3 Crystallization of MtUPRT………………………………………38 
2.2.4 Data collection and structure solving…………………………….39 
2.2.5 M. bovis BCG culture conditions, selection of spontaneous 
mutants against 5-fluorouracil and sequencing of upp gene.…….39 
2.2.6 5FU susceptibility of 5FU resistant mutants with MtUPRT 
mutations…………………………………………………………40 
2.3 Structure and mapping of spontaneous mutational sites of PyrR from 
Mycobacterium tuberculosis…………………………………………………41 
2.3.1 Cloning expression and purification of PyrR…………………….41 
2.3.2 Crystallization of PyrR-5FU complex…………………………...42 
2.3.3 Data collection and structure solving…………………………….42 
vi 
 
2.3.4 M. bovis BCG culture conditions, selection of spontaneous 
mutants against 5-fluorouracil and sequencing of pyrR gene……43 
2.3.5 5FU susceptibility of 5FU resistant mutants with PyrR 
mutations…………………………………………………………44 
3 Molecular genetics of FQ resistance……………………………………….45 
3.1   DNA gyrase- fluoroquinolone target…………………………………...46 
3.2   Mechanism of action of fluoroquinolones……………………………...46 
3.3   Fluoroquinolone resistance……………………………………………..48 
3.4   Molecular genetics of fluoroquinolone resistance……………………...48 
3.5   Objectives………………………………………………………………51 
3.6   Results…………………………………………………………………..52 
3.6.1 Selection and sequence analysis of M. bovis BCG 
spontaneous mutants at 5 μM MXF……………………………...53 
3.6.2 Frequency of mutation and mutation types of M. bovis BCG 
against the six FQs at 5 μM- Preliminary data…………………..55 
3.6.3 Frequency of spontaneous mutations at varying 
 FQ concentrations……………………………………………….57 
3.6.4 Distribution of SNPs across DNA gyrase of the FQ resistant Mtb 
strains- H37Rv and CDC1551…………………………………...59 
3.6.5 Comparison of frequency of mutant types selected 
 at varying fluoroquinolone concentrations……………………...66 




3.6.7 Mutant Prevention Concentration………………………………..79 
3.7   Discussion………………………………………………………………82 
3.8  Future directions…………………………………………………….......86 
 
4 Structural basis of mapping the spontaneous mutations with 
5-fluorouracil in uracil phosphoribosyltransferase from Mycobacterium 
tuberculosis…………………………………………………………………87 
4.1 Role of MtUPRT in pyrimidine biosynthesis - Salvage pathway……….88 
4.2 MtUPRT as a potential target in Mtb…………………………………….90 
4.3 Objectives………………………………………………………………..90 
4.4 Results……………………………………………………………………91 
4.4.1 MtUPRT purification and characterization………………………91 
4.4.2 Structure of MtUPRT…………………………………………….94 
4.4.3 Mapping of spontaneous mutations, that confer 5FU resistance in 
Mtb, on the MtUPRT structure…………………………………...99 
4.4.4 5FU susceptibility of 5FU resistant mutants harboring	alterations	
in	MtUPRT……………………………………………………...102 
4.5 Discussion………………………………………………………………103 
4.6 Future directions………………………………………………………..104 
5 Structure and mapping of spontaneous mutational sites of PyrR from 
Mycobacterium tuberculosis……………………………………………….105 
5.1 Role of PyrR in pyrimidine biosynthesis……………………………….105 





5.4.1 Mtb PyrR purification and characterization…………………….107 
5.4.2 Structure of PyrR……………………………………………….109 
5.4.3 Mapping of spontaneous mutations, that confer 5FU 
resistance in Mtb, on the PyrR-5FU structure…………………..117 
5.4.4 5FU susceptibility of5FU resistant mutants harboring	alterations	
in	PyrR………………………………………………………….118 
5.5 Discussion………………………………………………………………120 














Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(Mtb). In 2013, 9 million new active-TB cases were estimated globally and 1.4 
million TB-related deaths were recorded (CDC). Although the current drugs are 
effective against TB they are challenged by the emergence and spread of drug 
resistant TB at an alarming rate (Zumla & Grange, 2001). Approximately 1 in 13 
Mtb clinical isolates currently shows a form of drug resistance (CDC, 2009). The 
rise in multidrug resistant (MDR) and extensively drug-resistant (XDR) cases 
results mainly due to poor or non-compliance of patients (owing to the long 
treatment duration and side effects) and the characteristic ability of Mtb to go into 
non-replicating or dormant state (Gengenbacher & Kaufmann, 2012). The 
situation is further exacerbated by the increase in co-infection with human 
immunodeficiency virus (HIV) which compromises the TB therapy. Together 
these factors present a major challenge to TB control and underscore the need for 
the identification of novel anti-TB entities (O'Brien & Nunn, 2001, Fogel, 2015) 
that can shorten the TB treatment duration (Ma et al., 2010). However, 
inappropriate use of drugs and drug regimens is unavoidable resulting in the 
inevitable emergence of resistance. To avoid this issue optimal formulation of 
dosing strategy and development of efficient diagnostic tools for detecting 
resistance in the existing and newly introduced drugs is imperative to the control 
of emergence of resistance. Concomitant to the design and development of novel 
drugs, exploring novel drug targets in Mtb is required immediately (Ramaswamy 
& Musser, 1998). Thus, this thesis delves into applying molecular genetics 
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approach firstly to understand the fluoroquinolone (FQ) resistance and secondly, to 
explore drug targets in Mtb. 
To understand the basis of selection of FQ resistant mutants, 669 FQ resistant Mtb 
mutants were analyzed for their allelic diversity. Newer generation FQs, 
gatifloxacin and moxifloxacin, were the most potent and exhibited lowest 
mutation frequency. Enrichment of DNA gyrase variants depended on the type 
and concentration of FQ used. At higher FQ concentrations, only high-level 
resistant mutants occurred and importantly, mutant prevention concentration 
could be reached with all FQs. However, low level resistant mutants showed 
increased inhibitory concentrations emphasizing their importance in clinical 
setup. All the six FQs exhibited cross resistance and called for consideration of re-
designing the FQ formulation in TB regimen. 
Concomitantly, we identified two probable Mtb target enzymes namely, Mtb 
uracil phosphoribosyltransferases (UPRTases) and pyrimidine operon regulatory 
protein (PyrR) from the essential pyrimidine biosynthesis pathway, with the 
activity UPRTase.  Here we report the structures of MtUPRT and PyrR-5-
fluorouracil complex (PyrR-5FU) for the first time. 5FU is uracil (an UPRTase 
substrate) analogue, has anti-tuberculous activity and mutations in these two 
enzymes on 5FU exposure implicate their interactions with 5FU. Both 5-
phosphoribosyl 1-pyrophosphate (PRPP, another UPRTase substrate) and uridine 
monophosphate (UMP) binding sites are conserved in the above enzymes. 
Spontaneous mutational sites of mutants selected on 5FU mapped to either 
conserved or substrate binding residues. Structural insights in these two proteins 
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and the protein-5FU complex would aid in the screening of their inhibitors and 
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Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(Mtb) (Barnes, 2000). TB primarily affects the lungs (pulmonary) but can also 
affect other organs (extra-pulmonary). In 2013, TB claimed 1.5 million lives 
along with estimated 9 million new active cases (WHO, 2014). About one third of 
the world population harbors this pathogen as latent TB infection (LTBI), 5-10% 
of which has a probability to progress into an active TB infection. Consequently, 
efforts are being made worldwide to control the spread of this infection. As a 
result, recent years have witnessed slow decline in the number of active TB cases 
(37 million lives were saved between 2000 and 2013 through effective diagnosis 
and treatment) (WHO, 2014). The current 1st line anti-TB treatment is a 
combination therapy comprising of isoniazid (INH), rifampicin (RIF), 
pyrazinamide (PZA) and ethambutol (EMB) (Beena & Rawat, 2012). The 
emergence and spread of multidrug resistance TB (MDR TB, defined as isolates 
resistant to at least INH and RIF) and extensively drug resistance TB (XDR TB, 
MDR isolates additionally resistant to fluoroquinolone (FQ) and at least one 
injectable- aminoglycoside or capreomycin) at an alarming rate is rendering the 
existing drugs inefficient (Zumla & Grange, 2001). Approximately 1 in 13 Mtb 
clinical isolates currently shows a form of drug resistance (Figure 1.3) (CDC, 
2009). However, the drug resistant TB strains emerged since the mid-1980s with 
the co-infection by HIV (Human immunodeficiency virus), the major risk factor 
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for LTBI to progress into an active infection. The rise in MDR and XDR cases 
results mainly due to poor or non-compliance of patients (owing to the long 
treatment duration and side effects) (Lipsitch & Levin, 1998) and the 
characteristic ability of Mtb to go into non-replicating or dormant state 
(Gengenbacher & Kaufmann, 2012). The situation is further exacerbated by the 
increase in co-infection with HIV (Schluger et al., 2013). Together these factors 
present a major challenge to TB control and urge for the identification of new 
anti-TB entities (O'Brien & Nunn, 2001). 
 
1.1 Tuberculosis:	etiology	and	epidemiology	
In 1882, Robert Koch demonstrated Mtb as the etiologic agent of TB (Barnes, 
2000). Mtb are rod-shaped, non-motile, acid-fast bacilli and belongs to the 
Mycobacterium tuberculosis complex (MTBC) which consists of other 
Mycobacterium species that cause animal and human tuberculosis. Mtb has been 
evolving with its obligate human host for more than 70,000 years (Warner & 
Mizrahi, 2013). Mtb is an aerobic bacillus predominantly affecting the aerated 
organs- the lungs, however, it is known to survive anaerobically (as latent TB 
infection, LTBI) and harbors in one third of the world population. The replication 
time of Mtb is around 18 – 24 h (E. coli replication time is 20 min). The complex 
cell envelop consisting of high and varied lipid content in this pathogen accounts 
for many of its unique clinical characteristics and virulence (Espinosa-Cueto et 
al., 2015). Mtb evades the host macrophage defense mechanism by preventing its 
3 
 
integration into lysosomes aiding in the survival of Mtb (Pieters, 2001). These 
intrinsic characteristics of this unique bacterium thus pose a blockage to the 
development of effective therapeutics. 
TB has haunted mankind since prehistoric times. It was thought to be on the verge 
of eradication after the introduction of the first line anti-TB drugs (INH and RIF) 
in 1950s however, it resurge back in 1980s. Social change during the 
industrialization in the 17th to 20th century also contributed to increase in the TB 
incidence. The TB epidemics was directly proportional to the extent of 
urbanization; peaking at different places at different times (Lonnroth et al., 2009). 
Currently, longer treatment duration (resultant non-compliance which is partly 
related to socio-economic gradient) and the co-infection with HIV are amongst 
the top risk factors fueling the spread of drug resistant tuberculosis (Figure 1.1). 
Key 2013 TB facts: 9 million people fell ill with TB and 1.5 million died from it 
(among these deaths 0.36 million were people who were HIV – positive). There 
were an estimated 480 000 new cases of multidrug - resistant TB(2013) 















Mtb is an obligate human pathogen and its transmission occurs through inhalation 
of aerosols from an infected person to a healthy individual. Around 10 bacteria 
are enough to cause the Mtb infection (Nikas et al., 2005) which, depending on 
the individual’s immune status, progresses into an active disease or remains latent 
in most of the cases. Mtb invades the host immune system by first invading the 
alveolar macrophage with help of its multiple cell receptors (Ernst, 1998) which 
contains Mtb in vacuole and helps Mtb to be transported into deeper lung tissues. 
The survival strategies of Mtb, namely robust cell wall, upregulation of genes 
involved in lipid metabolism, tolerance to low pH, damage repair and 
detoxification,  help it to combat the hostile macrophage environment 
(Gengenbacher & Kaufmann, 2012). The infected macrophage continues to 
recruit other macrophages leading to formation of granuloma. Granuloma consists 
of an organized aggregate of differentiated macrophages and other immune cells 
(Figure 1.2). Furthermore, Mtb has the capability to shut down its central 
metabolism system and enter a non-replicating stage which activates on the 
weakening of the host immune system. 
The lipid rich Mtb cell envelope provides lipid mediators for the survival during 
replication and persistence (Glickman & Jacobs, 2001). The genes in these 







Figure	 1.2	 Pathogenesis	 of	Mycobacterium	 tuberculosis	 (Cambier	 et	 al.,	
2014).	 Aerosol	 particles	 containing	 active	 bacteria	 help	 the	 spread	 of	 TB.	 These	
bacteria	 infect	 the	 macrophages	 in	 lungs	 which	 transport	 the	 bacteria	 to	 deeper	















The live M. bovis Bacillus Calmette-Guerin (BCG)vaccine is the only available 
preventive measure against TB since 1921 (Stefanova, 2014) and will remain as 
golden standard while the new anti-TB vaccine development is in progress 
(WHO). However, it provides protection in only some populations and with 
compromised efficacy. Thus, BCG vaccination alone is not adequate for 
protection against active TB and calls for improved vaccination strategy (Hawn et 
al., 2014). Several clinical trials are ongoing to either boost the BCG 
immunization or evaluate the novel vaccines (Rowland & McShane, 2011). 
 
1.4 Diagnostics	
Few of the symptoms for suspected TB patients are coughing for more than 3 
weeks, weight loss, night sweats and fever. Such patients are referred to carry out 
the TB diagnostic tests which comprise of phenotypic and genotypic analysis. 
The conventional diagnostic tools: The preliminary diagnostic tool used to 
detect the presence of pulmonary TB lesions is a chest X-ray; however the 
technique can detect the infection only in the advanced stage. Sputum smear 
microscopy of stained acid-fast-tubercle bacilli is another conventional and 
commonly used technique. The false positive result due to presence of other acid-
fast bacilli is the drawback of this technique and thus complemented by culturing 
the samples in liquid or on solid media, called drug susceptibility testing (DST). 
DST provides information on effectiveness of treatment administered by 
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monitoring the culture conversion. DST is also useful to detect and monitor drug 
resistance. Nonetheless, culturing requires weeks before the result is acquired and 
is undesirable in high TB and HIV incidence setting. These diagnostic tools are 
century old and are associated with limitations and thus inefficient for the 
effective control and spread of TB (Perkins & Cunningham, 2007).Advances in 
liquid cultures systems have led to reduction in result obtaining time to days with 
the developments of BACTEC and MGIT automated liquid culture systems 
(Becton Dickinson). 
Advances in active TB diagnosis include improvement in the existing DNA 
amplification and immunological assays (Pai et al., 2006b). Nucleic acid 
amplification tests (NAAT) directly amplify the nucleic acid specific region from 
Mtb complex; however it is associated with low sensitivity and requires trained 
personnel. Immunological assays detect the humoral immune response that relies 
on antibody detection, however, currently only active TB can be detected with 
this technique. Another technique that detects growing bacteria colorimetrically is 
the TK medium (Salubris, Inc., MA, USA). This rapid culturing technique allows 
early detection than the conventional culturing technique and can be used for 
DST. 
Active TB also develops on reactivation of the LTBI. Until recently, LTBI could 
be quantified by the immunological Mantoux tuberculin skin test (TST) by 
injecting tuberculin purified protein derivative (PPD) intradermally in the 
forearm. The dimension of the hardened and elevated area at the injection spot is 
recorded for verifying the TB infection. However, low specificity is the limitation 
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of this test; it could be either positive (if the person was exposed to non-
tuberculous bacteria or BCG vaccination) or negative (due to inability to react to 
skin test due to weakened immune system) (CDC factsheets 2012). 
Advances in LTBI diagnosis: The specificity for accurate detection of Mtb is 
now possible due to the introduction of Mtb specific antigens (e.g. early secreted 
antigenic target (ESAT)-6, culture filtrate protein (CFP)-10 and TB7.7 (Rv2654)) 
in the interferon-γ release assays (IGRAs). These antigens sensitize the Mtb T-
cells which is measured in vitro by the IGRAs. IGRAs show lower cross 
reactivity to BCG vaccination than the TST(Andersen et al., 2000). Currently 2 
commercial IGRAs are available 1) QuantiFERON®-TB Gold In-Tube test 
(QFT-GIT) and 2) T-SPOT®.TB test (T-Spot). The limitation of this technique is 
its inability to distinguish between active and latent TB and also, due to the fact 
that only limited data is available on 1) prediction of relapse of TB and 2) TB 
detection in children and HIV/ immunocompromised patients (Pai et al., 2006a). 
Diagnosis of drug resistant TB: GenoType MTBDRplus and GenoType 
MTBDRs by Hain are the commercial NAAT-based line probe assays used for the 
detection of 1st and 2nd line drugs. With simultaneous detection of Mtb infection 
these assays amplify the regions of drug resistance with a sensitivity and 
specificity of 98.4 and 98% respectively for rifampin resistance (Ling et al., 
2008). However, only the predominant mutational sites (high-level resistance 
mutations; selected at higher drug concentration) are evaluated. Studies show that, 
low-level resistance mutations have the capacity to progress into increased 
resistance (Baquero, 2001). Capturing such mutations at the first step of resistance 
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diagnosis would aid in the further limit the emergence of resistance. 
Consequently, examining the resistance level offered by these low-level mutations 
forms one of the objectives of this thesis. 
An alternative cost effective technique is the microscopic-observation drug-
susceptibility assay (MODS), which uses sputum sample cultured in anti-TB 
drugs to detect cord formation using an inverted light microscope within 7 days 
(Nyendak et al., 2009). WHO recommends automated liquid culture systems as 
the ‘gold standard’ for first-line and second-line DST. However, the latter 
(second-line DST) is complex and expensive. Molecular line probe assays for 
first-line DST is another gold standard recommended by WHO. 
In parallel, for HIV endemic regions, the HIV infection test is recommended for 
rational formulation of both TB and HIV drug regimens. 
All the diagnostic tools are associated with drawbacks and are encouraged to be 
used in combination. However, the endemic countries mostly rely on the 
conventional tools for identification of resistant TB. Thus, in spite of the current 
advances in diagnostics the detection rate is still lower in the endemic countries in 
part, due to the inefficiency of the diagnostic tools (Wallis et al., 2010) and in 
part, due to the unavailability of the tools. Modeling studies show that 22% of 
global TB deaths can be averted with development of diagnostic tools that are 
unaffected by HIV status and have a sensitivity of at least 85% for smear positive 
and smear negative cases (Keeler et al., 2006). Additionally, XDR diagnosis still 
remains unstandardized due to involvement of more drugs and inadequate 
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information on the mutations associated with the drug resistance (Pai & O'Brien, 
2008). 
Comprehensive molecular genetics for all drugs is hence essential to efficiently 
design the diagnostic tools which would aid in the appropriate formulation of 
treatment strategy for resistant strains. The study of molecular genetics of 
resistance in one of the chemical class of compounds, the FQs (some of which are 















Implementation of several treatment strategies by WHO in the past decades have 
contributed to considerable TB control. The strategies include DOTS (Directly 
Observed Treatment Short-course) and several version of DOTS (For example, 
RNTCP in India), Stop TB (WHO, 2006-2015), and End TB (WHO, 2015). 
Treating new TB cases 
Multidrug therapy is used to treat TB to avoid the emergence of resistance. 
Currently the first line drug regimen includes INH (H) (300 mg), RIF (R) (600 
mg), PZA (Z) (25 mg/kg), and EMB (E) (15 mg/kg) for 2 months (daily, intensive 
phase) and INH (300 mg), RIF (600 mg) for 4 months (daily or 3 times weekly by 
DOTS, continuation phase) (Table 1.1) (WHO, 2015). Overall, daily dosing is 
recommended and the sputum is monitored during the treatment duration. For 
treating populations with high INH resistance, EMB is suggested to be included in 
















Applies  only  in  countries  with  high  levels  of 
isoniazid  resistance  in  new  TB  patients,  and 
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Treating resistant TB 
Controlling resistant TB is a major hurdle to the global TB control program. For 
previously treated patients (high likelihood of MDR-TB) DST (at least for INH 
and RIF) is recommended before formulation of treatment strategy which is thus 
individualized based on the DST results. For MDR-TB, patients are treated with 
the first line drug to which the Mtb is susceptible in combination with the second 
line drugs- ρ-aminosalicylic acid (PAS), cycloserine, FQs, aminoglycosides, 
polypeptides and ethionamide. Treating the resistant strains (MDR and XDR) 
requires expensive and toxic drugs with longer treatment duration which leads to 
patient non-compliance and further emergence of highly resistant strains. 
Treating latent TB 
The standard treatment for latent TB treatment is INH for 6 to 9 months. Most of 
the anti-TB drugs work on actively growing bacteria. Recent studies show that 
treating latent TB bacteria could play a major role in halting the progression into 
active TB infection. Exploring targets in latent stag e of TB could help in 
development of chemical entities that could potentially inhibit the growth of latent 
TB strains. Correspondingly, the second aim of this thesis was to partially validate 






Treating TB-HIV co-infection 
The standard regimen, 2HRZE/4HR, is administered daily irrespective of HIV 
status followed by HIV serology test. TB-HIV coinfection is recommended to be 
managed by experts in both diseases due to the pharmacological interaction 
between rifampicin and 2 groups of drug that are used in highly active 
















Penicillin was the first antibiotic discovered by Alexander Fleming in 1928 
(Florey, 1944). It was one of the successful antibiotics in the golden era of novel 
antibiotic classes to treat infectious diseases. However, penicillin-resistance 
occurred within 4 years of its mass production (Aminov, 2010) in spite of the 
warning against the use of sub‐therapeutic doses or non-lethal quantity of 
antibiotics (when bought without prescription). There are 3 possible mechanisms 
for bacterial resistance to occur: by adaptation (robustness of cells), by 
spontaneous mutations prior to exposure of antibiotics or by induced mutations on 
exposure to antibiotics. Resistance can also occur by horizontal transmission of 
resistance genes which is not observed in Mtb. Spontaneous mutations constantly 
occur in prokaryotes at a rate of 0.0033 mutations/ DNA replication. Induced 
mutations in Mtb arises due to several factors including misuse of drugs from the 
TB drug regimen, exposure of immunocompromised patients or by direct 
exposure to drug resistant TB. 
Misuse of drugs in TB treatment could arise due to the following reasons: 
1) Long duration of treatment (6-9 months) causing patient to leave treatment 
halfway. 
2) Exposure of Mtb to sub-optimal concentrations of drugs and thus 
unknowingly selecting for low-level resistant Mtb strains. (FQs are also 
used in treatment of other infectious diseases) 
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3) Dosing strategy rendered inefficient due to limited information of type of 
mutant strain selected. 
4) Very few drugs are available for treating latent TB, which harbors in one 
third of the world population. 
Weakened immune system due to other clinical conditions and medications leads 
to ineffective host defense (such as co-infection by HIV, diabetes, cancer, 
malnutrition, etc.). In addition, incompatibility of the treatment drugs and hence 
manipulation of the standard therapeutic strategy also leads to emergence of drug 
resistance. For example, the retroviral drugs interact with the anti-tuberculous 
drugs, particularly rifamycins. In such cases experts are required to design the 
appropriate therapy, which in many cases (developing countries with high TB and 
HIV burden) is not feasible. 
In addition, overpopulating metropolitan cities provide the niche for direct spread 
of resistant strains in healthy individuals (Figure 1.3). Negligence of evaluation of 
the resistance status in such cases, partly due to lack of appropriate and 
convenient diagnostic tools further burgeons the emergence of resistance 
1.6.1 MDR, XDR and TDR 
Drug resistance in TB is characterized as MDR, XDR and more recently TDR 
(Totally Drug Resistant).The definitions of some terms used in drug resistance as 
mentioned by Jeon et al. are quoted in Table 1.2. 
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The spread and emergence of resistance globally are depicted in Figure 1.3. As 
can be seen from the figure, complete picture of the spread of resistance is yet, 
either not available or only subnational data is available, for most of the 
developing (resource limited) countries. Convenient and inexpensive diagnostics 
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A rapid diagnosis of drug resistance and the subsequent initiation of an 
appropriate treatment are crucial in the management of drug-resistant TB. Using 
current recommendations, drug-resistant TB can be largely cured with the right 
combination and use of available anti-TB drugs provided efficient diagnostic tools 













1.6.2 Fluoroquinolones for drug resistant TB 
The very low minimum inhibitory concentration (MIC) of FQs and their potential 
to shorten TB therapy make them attractive candidates to counterbalance the 
failing TB therapy. FQs are nalidixic acid derivatives with broad spectrum anti-
bacterial activity particularly against resistant Mtb (Figure 1.4) (Drlica & Malik, 
2003). FQs  belong to the quinolone family discovered in 1962; since then there 
has been no new structural class of antibiotics for four decades (Walsh, 2003a). 
Of importance is the ability of chemical modifications to the quinolones that have 
led to development of second generation of quinolone derivatives with increased 
potency and wider spectrum of antibacterial activity, for instance, the FQs- 
levofloxacin (LVX) and ofloxacin (OFX), which are currently used to treat 
resistant TB (Beena & Rawat, 2012). FQs also show limited activity against some 
non-replicating mycobacteria, but activity against latent TB remains to be 
determined. 
Newer generation FQs, moxifloxacin (MXF) and gatifloxacin (GFX) were 
recently evaluated in phase III clinical trials to access their efficacy in the first 
line TB drug regimen to shorten the treatment duration from 6 to 4 months. The 
MXF containing regimen which replaced either INH or EMB exhibited rapid 
reduction in the bacterial load in the initial phase of treatment (Conde et al., 
2009), however, the shortened regimen was not observed to be non-inferior to the 
standard 6 month treatment and resulted in relapse (Gillespie et al., 2014). Similar 
results were obtained with GFX (Merle et al., 2014, Jawahar et al., 2013). 
Nevertheless, FQs are used in first-line treatment for multi-drug resistant (MDR) 
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TB and to treat patients with drug intolerance (Moadebi et al., 2007). Resistance 
to these valuable drugs is inevitable if their inappropriate use is not controlled 
(Moellering, 2005). Therefore, understanding the molecular mechanism of FQ 
resistance has received considerable attention in the scientific community since 
the development of these antibiotics. Correspondingly, evaluation of molecular 
genetic basis of resistance of the clinically used FQs is one of the main objectives 




Figure	 1.4	 Evolution	 of	 fluoroquinolones	 from	 nalidixic	 acid	 (Drlica	 &	







1.6.3 Molecular genetic basis of drug resistance 
In their original work, Luria and Delbruck suggest that if the number of mutants 
in multiple experiments is the same, then it is adaptive mutagenesis (Luria & 
Delbruck, 1943). In contrast, if the numbers differ it is spontaneous mutagenesis. 
However, experimental data since has shown that only extensive mathematical 
analysis using multiple data points can truly distinguish adaptive from 
















The pace of antibiotic development has reduced dramatically; for instance, there 
has been no new structural class of antibiotics for four decades after the 
introduction of quinolones in 1962 (Figure 1.5) (Walsh, 2003a, Barry & Cheung, 
2009). Nevertheless, past decade has witnessed a few drugs from 6 chemical 
classes that entered the clinical development pipeline (Figure 1.6) (Zumla et al., 
2013). Amongst the Phase III drugs, 3 are repurposed TB drugs: rifapentine and 2 
FQs (GFX and MXF). However, randomized clinical trials of 4 month regimen 
containing GFX and MXF were not found to be non-inferior to the current 6 
month regimen (Jawahar et al., 2013). Nevertheless, these are promising drugs 
against MDR TB, and given that the older generation FQs are already in use 
against other clinical conditions (mostly bacterial infections), emergence of Mtb 
resistance to the newer FQs (GFX and MXF) is inevitable. Understanding the 
mutant prevention ability and the resistance mechanism of these FQs would 
greatly aid in the rational dosage formulation strategies and molecular diagnostics 
against resistant Mtb strains. Correspondingly, this thesis delves into the 

















Nonetheless, the promising FQs are still at risk of emerging with resistance due to 
either misuse or cross resistance (owing to the identical mechanism of action as 
that of the older FQs). Thus, concomitant, identification of new drug targets 
(unique mechanisms of action) in Mtb is another promising approach to control 
TB (Beena & Rawat, 2012). 
One third of the world population is infected by dormant TB. Consequently, 
relapse in treated patients with the emergence of drug resistance as a result of 
(mostly) reactivation of dormant Mtb is a major concern. Mtb attains this latency 
by shutting down the central metabolism and replication; while at same time 
initiating the energy saving pathways for survival (Gengenbacher & Kaufmann, 
2012). Thus, genes involved in these metabolic pathways of non-replicating or 
dormant bacteria are attractive anti-tubercular drug targets .Also, taking into 
account the fast evolving Mtb, repurposing of drugs is an excellent approach for 
accelerated drug development with the possibility to discover new targets. 
1.7.1 Repurposing of drugs for TB treatment: 5-fluorouracil and its 
analogues 
Developing an entirely new drug requires detailed information on 
pharmacokinetics, toxicity and formulation which is usually time consuming and 
expensive (Kale et al., 2015). Repurposing of drugs holds promise to deliver 
faster and safer drugs, due to in-advance availability of such information 
(Ashburn & Thor, 2004). Correspondingly, 5-fluorouracil (5FU) is a clinically 
validated anticancer drug and recently being investigated for its mechanism of 
action in Mtb (Singh et al., 2015). The mechanism of 5FU resistance in Mtb was 
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demonstrated to be associated with mutations in the two enzymes with uracil 
phosphoribosyltransferase activity (UPRTase; EC 2.4.2.9). The enzymes are 
uracil phosphoribosyltransferase (MtUPRT) and pyrimidine operon regulatory 
protein (PyrR), encoded by the upp and pyrR genes respectively. 
Antitubercular activity of 5FU is known since 1979 (Tsukamura, 1979), however, 
it was not pursued as a potential TB drug given the toxic side effects of 5FU. 
Although, 5FU cannot be repurposed as an anti-TB drug, its analogues (on 
chemical modifications) can be evaluated in a target based drug discovery 
approach (Duncan, 2004), provided, structural insights into 5FU interactions with 
MtUPRT and PyrR are available. Subsequently, the understanding of these 
interactions with the help of molecular genetics approach (spontaneous mutants 
generated against 5FU) and structure determination of the enzymes involved 
forms the basis of second half of this study and is discussed in the latter part of 
this thesis. 
1.7.2 Identification of novel targets for TB drug development 
Essential biological pathways associated with DNA/RNA synthesis are often 
interrogated for favorable drug target enzymes (Duncan, 2004). There is ongoing 
research on Mtb metabolic pathways to understand this adaptation to persistence 
however, its complex nature makes the discovery of potential regulators evasive 
(Manabe & Bishai, 2000). 
In our previous study, Mtb H37Rv spontaneous mutants obtained on 5 µM and 20 
µM 5FU were screened for nucleotide polymorphisms in the pyrimidine synthesis 
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and salvage pathway enzymes- PyrR and MtUPRT respectively (Mathys et al., 
unpublished data). Intriguingly, all resistant alleles selected on 5 µM and20 µM of 
5FU had mutations on upp and pyrR respectively. In addition to the above 
observation, the expression of these two enzymes in different stages of Mtb makes 
it compelling to understand the underlying mechanism and to thereby progress 
one step further in their validation as potential Mtb targets. Structural insights into 
5FU interactions with these two enzymes form the basis of the study discussed in 
chapters 4 and 5. 
The two main objectives of this research work are based on the two backbones (1 
and 3) of the End TB strategy (2015) (WHO). The backbones of the End TB 
strategy are quoted as below: 
1) “Early diagnosis and treatment of all kinds of TB patients. 
2) Policies for political and community commitment towards TB care and 
prevention, including the universal health coverage policies. 
3) Intensified research and innovation for drug or target discovery, 









Irrespective of the effectiveness of combination therapy, emergence of resistance 
continues to pose a major challenge to TB control. One of the two main purposes 
of this study was to evaluate the potential of chemical genetics in our 
understanding of mechanisms of resistance and drug discovery. Six different FQs 
were used as model drugs in this study and their evaluations are discussed in 
chapter 3.  
The specific objectives in the first part of this study were as follows: 
1 To understand the molecular genetics of fluoroquinolones resistance 
1.1 To determine mutation frequency and frequency of mutation type selected 
on different clinically used FQs at varying concentrations. 
1.2 To determine the MICs of all FQs and the level of resistance exhibited by 
various mutant types. 
1.3 To determine cross resistance patterns exhibited by different mutants types 
selected on different FQs and at different concentrations 
1.4 To evaluate the mutant prevention concentration (MPCs) for the six FQs. 
Part	II‐	Structural	studies	of	two	key	pyrimidine	biosynthesis	enzymes	 
The second purpose of this thesis was to utilize chemical genetics to identify new 
mechanisms of resistance or targets for existing drugs. In this study we 
investigated the mechanism of resistance or targets of the anti-cancer drug 5-
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fluorouracil (5FU) in Mtb the findings of which are discussed in chapters 4 and 5 
respectively. 
The specific objectives in the second part of the study were as follows: 
2 To explore and validate new mycobacterial targets for TB drug development. 
2.1 To determine the structure of MtUPRT. 
2.2 To determine the co-crystal structure of PyrR-5FU complex. 
2.3 To establish the correlation between the spontaneous mutational sites of 
MtUPRT and PyrR with the 5FU resistance. 
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2.1.1 Mycobacterial strains and culture conditions 
Liquid cultures of M. bovis BCG, Mtb- H37Rv and Mtb- CDC1551 were obtained 
in 1 liter roller bottles containing 50-100 ml Middlebrook 7H9 media 
supplemented with 10% ADS (Albumin Dextrose Saline), 0.05% Tween80 and 
0.2% glycerol (called 7H9c). Agar plates with or without FQs prepared using 
Middlebrook 7H11 agar (supplemented with 10% OADC (containing Oleic acid, 
BSA, dextrose, Catalase powder and Sodium chloride) and 0.5% Glycerol), were 
used to grow the mycobacteria as colonies. The cultures were incubated at 37C 
until O.D.600 = 0.6-0.8 for liquid (7H9c media) cultures or until 3-4 weeks to 
obtain visible colonies on agar plates. BSL-3 facility was used for culturing the 
Mtb strains. 
2.1.2 Fluoroquinolones 
Gatifloxacin (GFX, cat.# G7298-1G), sparfloxacin (SFX, cat. # 56968-1G-F), 
levofloxacin (LVX, cat. # 28266-1G-F), ofloxacin (OFX, cat. # 08757-1G) and 
Rifampicin (RIF, cat. # R3501-1G) were obtained from Sigma life sciences. 
Moxifloxacin (MXF, cat.# 32477-50mg) and ciprofloxacin (CIP, cat. # 17850-
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5G-F) were obtained from Fluka analytical. Stock solutions of FQs at 10 mM 
were prepared in 0.1 N NaOH as required and stored at 4C. 
2.1.3 Recovery of spontaneous FQ mutants 
Liquid cultures of all strains were grown to log phase, O.D.600= 0.6 to 0.8. The 
cultures were centrifuged at 4000 rpm for 30 min and the pellet was resuspended 
in 7H9 media to obtain a stock cell density of approximately 1010 CFU per ml. 
Around 109 and 107 Mtb cells or CFU were applied on agar plates containing 1 
µg/ml Rifampicin (Control), GFX and MXF while 108 and 106 CFU were applied 
on SFX, LVX, CIP and OFX at varying concentrations. The plates were incubated 
at 37°C for 4-6 weeks before CFU counting. Dilutions of stock cultures were 
plated on 7H11 agar plates without antibiotics to calculate the initial CFU count. 
2.1.4 Sequence analysis of gyrA and gyrB of mutants  
All the colonies were picked from plates containing less than 10 colonies whereas 
~5-10 colonies were picked from plates containing more than 10 colonies. Mutant 
colony cultures were obtained by inoculating a single colony in 30 ml sterile 
bottles containing 5 ml 7H9 media and incubating at 37°C on table top shaker for 
2 weeks or until O.D.600 = 0.6. Mutant stocks were prepared in 1 ml 7H9c media 
containing 20% glycerol and stored in 2 ml screw cap tubes at -80°C. 
Colony PCR: About 1 ml of mutant culture was centrifuged, resuspended in 100 
µl of sterile water and heat-killed at 95°C for 20 min. The supernatant after 
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centrifugation was used as genomic DNA template for the PCR reaction to 
amplify the gyrA and gyrB genes of the mutants and sequenced. 
The DNA Gyrase- Subunits A and B encoding genes gyrA (2517 bp) and gyrB 




















2.1.5 Characterization of fluoroquinolone resistant mutants 
Minimum inhibitory concentration (MIC) (Pethe et al., 2010) 
a) Determination of MIC99:agar plates 
MIC99 is determined by visually analyzing the mycobacterial pellet formation in 
broth or colonies on agar. Agar plate MIC was determined for FQ resistant 
spontaneous mutants on 24-well agar plates with FQs at concentrations ranging 
from 0.1 μM – 50 μM. RIF plates were used as control antibiotic. ~5x104 cells 
were inoculated on the wells and incubated for 3 to 4 weeks at 37°C. The plates 
were visually analyzed for bacterial growth. The lowest concentration at which no 
growth was observed was noted as the MIC99. 
b) Determination of MIC50/ MIC90: Microplate dilution assay 
1ml of frozen mycobacterial stock at O.D.600 = 1.0 was inoculated in 50ml of 
7H9c media. The culture was incubated at 37°C until the O.D.600 reached 0.2 to 
0.3. Flat-bottom 96-well assay plates were spotted with FQs, RIF and 
streptomycin in the 2nd lane to give final concentration of 40 μM, 2 μM and 10 
μM in 200 μl of 7H9 respectively. This was further diluted 2-fold in the 
subsequent wells until concentration of 0.04 μM, 0.002 μM and 0.01 μM was 
reached for the above drugs respectively. The mycobacterial cultures were diluted 
to O.D.600 = 0.04 and 100 μl was inoculated in the assay plate. The plates were 
incubated under humid condition at 37°C for 5 days. SpectraMax M2 was used to 




2.1.6 Mutant prevention concentration (MPC) 
Liquid cultures of the Mtb strains were grown to stationery phase, pelleted and 
resuspended in fresh 7H9c media to obtain ~1x1010 CFU/ ml. Approximately 
2x1010 cells were applied to agar plates containing varying concentrations of 
GFX, MXF SFX, LVX, CIP and OFX. RIF plates were used as control with a 
inoculum of 1x109 CFU/ ml. Around 20 plates for each concentration for all FQs 
were used. The plates were incubated at 37°C for 4-6 weeks before CFU 
counting. The concentration of a given FQ at which no colonies were seen on all 





























2.2.1 Cloning, expression and purification of MtUPRT 
A 624 bp DNA fragment consisting of the upp gene was amplified by Taq 
polymerase using Mtb H37Rv genomic DNA as the template in a PCR reaction. 
The cloning primers contained the restriction sites BamHI and HindIII and were 
as follows: uppF 5' GGA TCC GTG CAG GTC CAT GTC GTT GAC 3' and 
uppR 5' AAG CTT TCA GCG CGG GCC GAA CTG GCG 3'. The purified PCR 
product was subcloned into pCR 2.1-TOPO vector and transformed in the 
chemically competent One shot TOP10 cells (Life technologies). 
Gateway cloning system (Life technologies) modified in house was used to 
generate the final expression vectors. The plasmid, isolated from the cells and the 
entry vector, pNAT745 (with attL1 and 2 sites) were digested with the restriction 
enzymes BamHI and HindIII and run on a 1% agarose gel. The digested gene 
fragment and the pNAT745 bands on the gel were purified using gel extraction kit 
(Qiagen) and ligated using the DNA ligation kit (Roche) followed by 
transformation into TOP10 cells. The pNAT745-upp plasmid was isolated and 
subjected to LR recombination reaction to clone the gene into four destination 
vectors, having the attR1 and 2 sites and with different affinity purification tags 
(His-S, MBP-His-S, NusA-His-S and Trx-His-S) followed by transformation into 
Tuner (DE3) competent cells (Novagen) E. coli cells to yield N-terminal tagged 
proteins. Transformed cells were grown in LB to a log phase culture (O.D600= 0.6 
37 
 
to 0.8) at 37°C in the presence of 30 μg/ml kanamycin, and then induced with 0.2 
mM isopropyl β-D-1-thiogalactopyranoside at 18°C for 20 h. Small scale 
expression and purification of the protein showed that the vector pNAT80 (His-S 
tag) expressed the protein with least impurities and was further used for large 
scale protein production. 
The purification protocol used was a modified version of the protocol described 
by Villella et al. (Villela et al., 2013). The overexpressed cells were harvested by 
centrifuging at 7500 g for 30 min. The cell pellet was resuspended and incubated 
in lysis buffer consisting of Buffer A (20 mM Tris pH 7.5, 300 mM NaCl) and 
lysonase (Merck) followed by sonication. The cell lysate was collected and 
treated with 1% (w/v) streptomycin sulphate for 30 min at 4°C and dialyzed 
overnight with 20 mM Tris (pH 7), 100 mM NaCl at 4°C. The lysate was then 
subjected to gradient elution on a MonoQ HR 16/10 column followed by affinity 
purification on HiTrap column. The eluted fractions were then applied to gel 
filtration column- HiLoad 16/600 Superdex 200 prep grade and eluted with Buffer 
A to get the isolated MtUPRT protein  (The purification columns used were from 
GE-Amersham). The purity of MtUPRT was analyzed using Novex 4–12% Bis-
Tris gels from Invitrogen (Carlsbad, CA, USA) and quantified using a standard 
Bradford assay. The eluted fractions were concentrated using Vivaspin 
concentrators (5 kDa cutoff) (Viva Products, Littleton, MA, USA).The aliquots of 




2.2.2 Dynamic light scattering (DLS) of MtUPRT 
The homogeneity of MtUPRT during concentrating was assessed intermittently 
using DLS. DLS measurements were performed at room temperature (298 K) on a 
DynaPro (Protein Solutions) DLS instrument (Wyatt Technology Corp., Santa 
Barbara, CA, USA). All samples were centrifuged at 18,000 g for 20 min prior to 
the experiments. Measurements were recorded at 18°C. 
2.2.3 Crystallization of MtUPRT 
The crystallization of MtUPRT was carried out at 8mg/ml concentration. 
Crystallization screening was done using the Phoenix Liquid Handling System 
(Art Robbins Instruments) with the high throughput reagent screens by Hampton 
and Qiagen. The ratio of protein to crystallization reagent in the crystallization 
drop was 1:1 (0.2μl each) and it was equilibrated with 40 μl of the reservoir 
reagent at 25°C. Crystals were observed in the Crystal screen I (Hampton 
Research, USA) condition number C10 (#34) consisting of 0.1 M sodium acetate 
trihydrate (pH-4.6) and 2 M sodium formate. However, owing to the smaller 
crystal size (<0.05mm) optimization of the precipitant concentration, reservoir: 
protein solution ratio and equilibration temperature were carried out. Grid screen 
with the above condition was manually set up with the precipitant, sodium 
formate, ranging from 1.5 to 3 M using the sitting drop vapour diffusion 
technique. The crystal drops were set up in duplicates in the following reservoir: 
protein solution ratios- 1:1, 1:2 and 2:1. The plates were equilibrated at 25°C and 
16°C. Macro- and micro-seeding techniques were also used during the further 
optimization of the crystals. Although the crystal could not be reproduced in the 
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manual grid screening, the micro-seeding (using cat whisker) technique was 
useful for reproducing the crystals.  The initially obtained crystals were diluted 10 
times with the reservoir solution and crushed using MicroSeed Beads (Molecular 
Dimensions) to generate microseeds or microcrystals. A fresh aforementioned 
grid screen was set up and several tiny microcrystals were streaked onto the new 
drops using a cat whisker. Notably, bigger and diffraction quality crystals were 
obtained using this technique with 2 M precipitant and drop ratio of 1:2 at 25°C. 
2.2.4 Data collection and structure determination 
MtUPRT crystals were soaked in a cryo-protectant solution consisting of the 
crystallization condition supplemented with either 50% glycerol or 
perfluoropolyether oil to optimize the cryo condition. The crystals were mounted 
on nylon loops and flash-cooled at -180°C in the nitrogen cold stream. The 
complete data set for MtUPRT was collected using the in-house Rigaku rotating 
anode generator (Microfocus rotating anode X-ray generator Rigaku 
MicroMax(tm)-007 HF). Two complete data sets consisting of 120 and 180 
images were collected with a 1° oscillation range at a wavelength of 1.5418Å. 
The data collection statistics are provided in Table 1. The data was processed with 
HKL 2000. 
2.2.5 Mycobacterium bovis BCG culture conditions,  selection of 
spontaneous mutants against 5-fluorouracil and sequencing of upp 
Mtb surrogate, Mycobacterium bovis BCG, was used to select for the spontaneous 
mutants with 5FU. MtUPRT from both strains are 100% identical. Liquid culture 
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of M. bovis BCG was obtained in 1 liter roller bottles containing 50-100 ml 
Middlebrook 7H9 media supplemented with 10% ADS (Albumin Dextrose 
Saline), 0.05% Tween80 and 0.2% glycerol. Middlebrook 7H11 agar plates, with 
or without 5FU were used to grow M. bovis BCG as colonies. The liquid cultures 
were incubated at 37°C until O.D.600 =0.6-0.8 (~1×108 CFU/ml; colony forming 
units). Around 1×108 CFU were applied on agar plates containing 5 and 20 µg/ml 
5FU. The plates were incubated at 37°C for 4 to 6 weeks. Mutant subcultures 
were obtained by inoculating a single colony in 30 ml sterile bottles containing 5 
ml 7H9 media and incubating at 37°C on table top shaker for 2 weeks or until 
O.D.600 = 0.6.  
Sequence analysis of Mtb upp: About 1 ml culture of mutant culture was 
centrifuged and the pellet was resuspended in 100 µl of sterile water and heat-
killed at 95°C for 20 min. The supernatant after centrifugation was used as 
genomic DNA template in the PCR reaction to amplify the upp gene of the 
mutants followed by sequencing. Following primers were used for PCR reactions 
and sequencing: 
SuppF  5’ ggacgcacccgtatcagcccc3’ 
SuppR  5’ cgcagcgaatctccaagtagc 3’ 
2.2.6 5FU	 susceptibility	 of	 5FU	 resistant	 mutants	 with	 MtUPRT	
mutations 
MIC50 were determined for the 5FU resistant mutants to evaluate their 





2.3.1 Cloning expression and purification of Mtb PyrR 
pyrR-pET28b construct (codon optimized for E. coli) was ordered from Genscript 
and was transformed in Tuner (BL21 DE3) competent E. coli cells (Novagen) to 
yield N-terminal His-tagged protein. The transformed cells were grown in Luria-
Bertani medium to a log phase culture (O.D.600= 0.6 to 0.8) at 37°C in the 
presence of 30 μg/ml kanamycin, followed by induction with 0.5 mM isopropyl β-
D-1-thiogalactopyranoside at 18°C for 20 h.  
The overexpressed cells were harvested by centrifugation at 7500 × g for 30 min. 
The cell pellet was resuspended in lysis buffer consisting of Buffer A (20 mM 
Bis-Tris pH 6.5, 200 mM NaCl, 5% Glycerol and 1mM DTT) followed by 
sonication.  The lysate was first processed by affinity chromatography using a 
HiTrap column (GE-Amersham). Subsequently, the eluted sample was applied to 
the HiLoad 16/60 Superdex 200 prep-grade gel filtration column (GE-
Amersham), and eluted with Buffer A. The purity of PyrR was analyzed using 
Novex 4–12% Bis-Tris gels which showed a single band at approximately 25 kDa 
(Invitrogen Carlsbad, CA, USA) and quantified using a standard Bradford assay. 
The eluted fractions were pooled and concentrated to 4 mg/ml using Vivaspin 20 
concentrators (5 kDa cut-off) (Viva Products, Littleton, MA, USA). The 
homogeneity of PyrR was further confirmed by Dynamic light scattering (DLS) 
experiments as mentioned in section 2.2.2. 
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2.3.2 Crystallization of PyrR-5FU complex 
The crystallization screening of PyrR (4 mg/ml) in the presence 5FU (ratio- 
1:100) was carried out manually. The ratio of protein to crystallization solution 
(Hampton Research, USA) in the crystallization drop was 1:1 (1 μl each); the 
drop was equilibrated with 450 μl of reservoir solution at 25°C using hanging 
drop method. The PyrR-5FU complex crystals were observed in the crystal screen 
I condition consisting of0.1 M imidazole pH 6.5, 1.0 M sodium acetate trihydrate. 
The above condition was optimized in grid screening combined with additive 
screen. Diffraction-quality crystals were obtained with the above condition in the 
presence of 10% v/v 1,2-Butanediol at 25°C. 
2.3.3 Data collection and structure determination 
The PyrR-5FU complex crystals were briefly soaked in 50% glycerol (cryo-
protectant) before they were mounted on nylon loops and flash-cooled at -180°C 
in a nitrogen cold stream. The complete dataset for Mtb PyrR-5FU was collected 
using the in-house Rigaku rotating anode generator (Microfocus rotating anode X-
ray generator Rigaku MicroMax-007 HF) using the Saturn 944+ detector. The 
data collection and structure statistics are provided in Table 1. The data was 
processed with HKL 2000 (Otwinowski & Minor, 1997). The Mtb PyrR structure 
solutions were obtained through molecular replacement method using Phaser 
program (McCoy et al., 2007). The coordinates from PDB: 1W30 were used as 
the starting search model. Six molecules of PyrR were observed in the 
asymmetric unit. The PyrR model was examined and built in COOT (Emsley & 
Cowtan, 2004). Phenix-refine was used for further refinement (Adams et al., 
43 
 
2010). The PyrR was modeled to fit in its substrates and 5FU followed by the 
refinements using the COOT and Phenix programs, respectively. The final 
structure was refined up to 2.6 Å resolution with an R-factor of 0.19 (Rfree 0.23) 
(Table 5.1) The overall geometry of the final model was analyzed by 
Ramachandran plot with the program (Chen et al., 2015). 
2.3.4 Mycobacterium bovis BCG culture conditions, selection of 
spontaneous mutants against 5FU and sequencing of pyrR gene 
As mentioned earlier Mtb surrogate, Mycobacterium bovisBCG, was used to 
select for the spontaneous mutants with 5FU. PyrR sequence from both strains are 
100% identical. Selection of spontaneous mutants on 5FU was carried out as 
mentioned in section2.2.5. 
Sequence analysis of Mtb pyrR: About 1 ml culture of mutant culture was 
centrifuged and the pellet was resuspended in 100 µl of sterile water and heat-
killed at 95°C for 20 min. The supernatant after centrifugation was used as 
genomic DNA template in the PCR reaction to amplify the pyrR gene of the 
mutants followed by sequencing. The primers listed below were used for PCR 
reactions and sequencing: 
SpyrRF1   5’ cgtgcgagtgctacgctgccg 3’ 





2.3.5 5FU susceptibility of 5FU resistant mutants with PyrR mutations 
MIC50 were determined for the 5FU resistant mutants to evaluate their 
























Inappropriate use of drugs selects for bacteria with new types of mutations 
resulting in inevitable emergence of resistance to antibiotics. Comprehensive 
information of molecular genetics of drug resistance mechanism is essential for 
appropriate formulation of dosing strategy, for the development of efficient 
diagnostic tools and for the development of new drugs or drug derivatives 
(Ramaswamy & Musser, 1998). Introduction of newer generation FQs was being 
considered recently to evaluate their efficacy to shorten the current 1st line anti-
TB therapy to 4 months (Bryskier & Lowther, 2002). FQs show broad spectrum 
anti-bacterial activity against both replicating and non-replicating mycobacteria. 
FQ mechanism of action involves inhibiting the DNA gyrase enzyme, resulting in 










DNA gyrase is a heterotetramer composed of two subunits of GyrA and two 
subunits of GyrB subunits (Blanchard, 1996). The catalytic core of DNA gyrase 
comprises of the C-terminal domain of GyrB and N-terminal domain of GyrA. 
DNA gyrase is an essential enzyme required in relaxation of supercoiled DNA 
during the process of replication, transcription and recombination. DNA gyrase 
accomplishes this function by generating double strand breakage in the DNA 
strands for strand passage followed by re-ligation of the strands (Figure 3.1). 
3.2 Mechanism	of	action	of	fluoroquinolones	
FQ mechanism of action involves interruption of DNA replication by inhibiting 
the DNA gyrase. FQs interact with the quinolone-binding pocket (QBP) of DNA 
gyrase within the catalytic core of the enzyme by forming a ternary complex with 
the DNA-DNA gyrase assembly (Figure 3.2) (Piton et al., 2010). This halts the 
re-ligation of the DNA strands leading to the inhibition of replication 
consequently resulting in cell death due to double-strand breaks (DSBs) in the 
DNA. The QBPs or the quinolone resistance determining regions (QRDRs) of the 
GyrA (QRDR-A; amino acids 74 to 113) (Takiff et al., 1994) and GyrB (QRDR-
B; amino acids 500 to 538) (Cole et al., 1998) are conserved regions. Mutations in 






















The introduction of FQs in the 1st line TB drug regimen is of concern due to 
emergence of resistance in Mtb particularly due to its wide use for treatment of 
other infections, for example urinary tract infections, community acquired 
pneumonia, typhoid fever and ocular infections (Singh et al., 2012, Field et al., 
2012). Mycobacteria are known to be intrinsically less susceptible to FQs; 
therefore acquired resistance is the only kind that can be controlled by rational 
formulation and use of these antibiotics. Understanding the molecular genetics of 
FQ resistance before designing treatment regimens and formulation strategies are 
hence critical for the clinical laboratories and the TB control program (Sun et al., 
2008, Drlica & Malik, 2003).  
3.4 Molecular	genetics	of	fluoroquinolone	
resistance	
It is known that most mutations (approximately 90%) associated with FQ 
resistance map to the QRDR-A and QRDR-B (Antonova et al., 2008, Mokrousov 
et al., 2008, Sekiguchi et al., 2007, Kocagoz et al., 1996). Consequently, majority 
of the studies are focused on the mutations located within the QRDR-A (Zhou et 
al., 2000, Devasia et al., 2012) and only recently, some investigations include 
those in QRDR-B (Pantel et al., 2012, Malik et al., 2012). Earlier reviews also 
revealed considerable discrepancies in the reported percentages of GyrA 
mutations ranging from 11% to 90%, while the GyrB mutations were not taken 
into account by most of the studies (Pitaksajjakul et al., 2005, Huang et al., 2005, 
Cheng et al., 2004, Yew et al., 2000, Giannoni et al., 2005). Additionally, the 
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mutations outside the QRDRs were not identified. Recent findings, indicating that 
mutations outside the hotspot (QRDR) confer resistance in clinical isolates 
(Devasia et al., 2012, Ginsburg et al., 2003, Pantel et al., 2012) calls for detailed 
assessment of these mutations. Such information would be useful in designing 
molecular diagnostic tests with better sensitivity and specificity. For the 
assessment of resistance and to get a comprehensive picture of all possible 
mutations on the DNA gyrase, we sequenced the entire gyrA and gyrB genes for 
318 Mtb- H37Rv and 351 Mtb- CDC1551 laboratory-generated FQ spontaneous 
mutants.  
Although newer FQs (MXF and gatifloxacin (GFX)) are generally more potent, 
their structures are based on the same scaffolds of existing FQ (example 
ciprofloxacin (CIP)) with minor changes (Figure 3.3); thus the inherent risk of 
cross-resistance remains a hindrance to proper treatment (Walsh, 2003a). In 
addition, there is a possibility of FQs been used in the treatment of other 
infectious diseases (for example, urinary tract infections and enteric fever) in 
patients prior to the activation of TB (Dalhoff, 2012). This prior exposure of Mtb 
to sub-optimal dose of other FQs leads to selection of low level resistance through 
cross-resistance to FQs used in TB treatment (Baquero, 2001). This mandates the 
understanding of cross resistance patterns amongst the FQs which will allow for 
rational formulation of an anti-TB drug regimen (Malik et al., 2012, Caminero, 
2006, Alangaden et al., 1995, Sirgel et al., 2012).  
Researchers have examined this significant aspect of cross resistance for the FQs. 
However, these studies included only a few of the clinically used FQs, for 
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instance, study done by Alangaden et al. included only CIP, levofloxacin (LVX), 
and sparfloxacin (SFX) (Alangaden et al., 1995). Also, collective inferences from 
these studies could be biased, as these studies used different Mtb strains namely 
clinical isolates (Sirgel et al., 2012), pathogenic or the attenuated laboratory 
strains (Kocagoz et al., 1996) by different research groups. Moreover, cross-
resistance patterns for the newer FQs- MXF and GFX (developed in 2000-2005) 
remain to be evaluated. 
Sindelar et al. proposed a significant approach to limit emergence of resistant 
strains due to selective drug pressure called the mutant prevention concentration 
(MPC) (Sindelar et al., 2000).  Their study showed that FQ concentrations in 
serum could be reached above the MPC and thus useful in designing effective 
dosing strategies that would limit emergence of resistant strains. These MPCs, 
however, have not been considered by most of the studies or have been reported 
for only one clinically used FQ (Zhou et al., 2000). 
FQ resistant strains or mutants emerge due to spontaneous mutations or SNPs 
(single nucleotide polymorphism) on the DNA gyrase when subjected to sub-
optimal or intermittent exposure to FQ concentrations (Drlica, 1999). Thus, 
molecular genetic studies and determining minimum inhibitory concentrations of 
these resistant strains are paramount to evaluate FQ resistance mechanism and 
selection of mutant types and thus under critical investigation (Xu et al., 1996). In 
this regard, we initially evaluated the effect of MXF selected M. bovis BCG 
mutants on the FQ resistance mechanism. Later we extended this study to 
examine FQ resistance mechanism in the Mtb strains- H37Rv and CDC1551 with 
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six clinically used FQs. The structures of the FQs used in this study are mentioned 





The specific objectives for the first part of the study were as follows: 
1) To determine mutation frequency and frequency of mutation type selected 
on different clinically used FQs at varying concentrations. 
2) To determine the MICs of all FQs and the level of resistance exhibited by 
various mutant types. 
3) To determine cross resistance patterns exhibited by different mutants types 
selected on different FQs and at different concentrations 





MXF is under evaluation ever since its inclusion in the 1st line therapy for TB has 
been considered (Blanchard, 1996). One way to assess this issue is to select for 
spontaneous mutants with MXF to identify and analyze the mutations that confer 
the low- to high-level resistance. Formulation of dosing strategies utilizes such 
information to determine the concentration that can maintain lowest or no 
mutational levels. It has been observed previously and in this study that, with 
increasing drug concentration (selection pressure) the type of mutation selected 
varies until specific variants that confer the highest resistance are selected with 
very low mutation frequency, while at low concentration various types of low-











3.6.1 Selection and sequence analysis of M. bovis BCG spontaneous mutants 
at 1.25 μM and 5 μM MXF 
In our initial experiment we determined mutation frequency of M. bovis BCG 
against 1.25 μM and 5 μM of MXF (2.5 and 10 times MIC99 respectively). The 
mutants were sequence analyzed to evaluate the different alleles of DNA gyrase 
that were selected. The mutation frequency was found to be 1×10-9 at 1.25 μM 
while there were no mutants recovered at 5 μM of MXF. In total, twelve mutants 
were recovered on 1.25 μM. Sequencing their QRDR-A and QRDR-B regions 
resulted in identification of SNPs only in QRDR-A at 2 positions, Gly88 and 














Cross resistance is another important challenge when drugs belonging to the same 
class are used in treatment regimens. Therefore, in our pilot study, we also sought 
to evaluate this phenomenon for the MXF resistant strains harboring the 
mutations- D94G, D94N, D94Y and G88C by determining the MIC99 of other 
FQs on agar plates. The six FQs used were as follows: GFX, MXF, SFX, CIP, 
LVX and OFX. The aforementioned MIC99 result showed that above MXF 
resistant strains were cross resistant to all the FQs and a slight shift towards 
higher MIC99 observed was in the order as follows: GFX < MXF/SFX/CIP < 
LVX < OFX (Table 3.2).  Interestingly, MIC99 shift was also observed within the 
strains depending on the resistant allele. MIC99 for the G88C variant was higher 
than the D94G/N/Y variants. 
 
Table	3.2	MIC99	of	FQs	against	M.	bovis	BCG	MXF	resistant	alleles.	
FQ (μM)  WT‐BCG  D94G  D94N  D94Y  G88C 
GFX  0.2  5  5  5  5 
MXF  0.5  10  10  10  20 
SFX  0.5  10  10  10  20 
LVX  0.5  20  20  20  20 
CIP  1  10  10  10  20 






3.6.2 Frequency of mutation and mutation types of M. bovis BCG against 
the six FQs at 5 μM- Preliminary data 
The mutation frequency of M. bovis BCG was found to be at 1×10-8 for OFX, CIP 
and LVX; 1×10-9 for MXF; between 1×10-8 and 1×10-9 for SFX. There were no 
mutants recovered on GFX above 5 μM. Interestingly, predominance of mutation 
type selected was dependent on the type of FQ used for selection (Table 3.3). For 
instance, MFX only selected the G88 variant, LVX selected mostly the D94 
variants whereas, OFX also selected the A90 variant along with D94. To analyze 
this phenomenon that the genotype (amino acid mutation in DNA gyrase) and the 
resistance phenotype (mutation frequency) depend on the type of FQ we selected 






frequency G88C D94Y D94N D94G A90V  S91P  Total
GFX  4th  <1.0×10‐9  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 
MXF  4th  1.1×10‐9  27  ‐  ‐  ‐  ‐  ‐  27 
SFX  3rd  1.6×10‐9  ‐  ‐  4  ‐  ‐  ‐  4 
LVX  3rd  1.0×10‐8  4  5  7  4  ‐  ‐  20 
CIP  2nd  1.3×10‐8  3  14  9  5  ‐  ‐  31 
OFX  2nd  3.0×10‐8  5  12  10  11  33  3  74 




It has been shown in CIP and its analogs that, apart from dependence of genotype 
or phenotype of mutants selected on these FQs, their concentration also affects the 
selection of mutant alleles (Zhou et al., 2000). Due to the broad-spectrum 
antimicrobial activity of FQs, they are widely used in treatment of other infectious 
pathogens at various concentrations. Therefore, we extended our study to 
comprehensively evaluate the drug concentration, mutation-type and frequency 
relationship amongst FQs in Mycobacterium strains. Mtb strains H37Rv and 
CDC1551 were used in a single experimental setup to recover spontaneous 
mutants on FQs to access the possibility of different strains harboring diverse 
mutation spectrums. FQ concentrations ranging from 0.1 μM to 50 μM were used. 
H37Rv is a virulent laboratory strain, whereas CDC1551 is a recent clinical 
isolate responsible for the TB outbreak during 1994 to 1996 with virulence 
comparable to H37Rv (Valway et al., 1998, Manca et al., 1999). CDC1551 has 
undergone several passages in laboratory since then. The proteome of these two 
strains was found to be highly similar (Betts et al., 2000). The GyrA protein 
sequence of both these strains is identical except at 3 residues (Glu21Gln, 
Ser95Thr and Gly668Asp) whereas the first 28 amino acids from the CDC1551 






3.6.3 Frequency of spontaneous mutations at varying FQ concentrations 
The mutation frequency of the Mtb strains and M. bovis BCG was ~1×10-8 at 0.5 
to 2 μM and 0.5 to 1 μM of GFX respectively, while no mutants were recovered 
above 5 and 2 μM respectively (Table 3.4). A similar mutation frequency (1×10-8) 
of the Mtb and BCG strains was obtained at 1 to 5 μM and 0.5 to 2 μM of MXF 
respectively. Similar mutation frequency was observed with SFX. For LVX the 
above frequency was observed at higher concentrations- 5 to 10 μM and 2 to 10 
μM respectively for the Mtb strains- CDC1551 and H37Rv,  whereas, for CIP and 
OFX these concentrations further increased to 5 to 20 μM and 5 to 10 μM 




































µM  GFX   MXF  SFX  LVX  CIP  OFX 
50  0  0  0  0  0  0 
20  0  0  0  0  0.75  1 
10  0  0  0  2.75  1.75  2.75 
5  0  2.5  2.25  2  2  4 
2  3  2.5  2.75  5.5  9.5  21.5 
1  3.4  3.25  4.5  16  L  L 
0.5  5  12.75  6.25  L  L  L 
0.2  L  L  L  L  L  L 
0.1  L  L  L  L  L  L 
[Note: Bacterial growth- L= Lawn or Confluent; DL= dispersed lawn or semi-confluent] 
µM   GFX   MXF  SFX  LVX  CIP  OFX 
50  0  0  0  0  0  0 
20  0  0  0  0  0  0 
10  0  0  0  0  3.5  0.25 
5  0  0  0  2  11  1.25 
2  0  1  1  2.75  46  6.75 
1  1  2.3  4  4  149  DL 
0.5  1.75  2.5  7  DL  L  L 
0.2  17.75  11.5  DL  L  L  L 
0.1  L  L  L  L  L  L 
µM  GFX   MXF  SFX  LVX  CIP  OFX 
50  0  0  0  0  0  0 
20  0  0  0  0  0.27  0.33 
10  0  0  0  0.33  1.83  3.36 
5  0  0.62  0.44  4.21  4.24  4.05 
2  2.18  2.72  1.36  ‐  ‐  ‐ 
1  2.32  6.1  4.75  ‐  L  L 
0.5  ‐  ‐  ‐  L  L  L 
0.2  L  L  L  L  L  L 
0.1  L  L  L  L  L  L 
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3.6.4 Distribution of SNPs across DNA gyrase of the FQ resistant Mtb 
strains- H37Rv and CDC1551  
To obtain a statistically significant data, 318 H37Rv and 351 CDC1551 mutants 
were selected for sequencing the gyrA and gyrB genes. Sequencing was not done 
in the M. bovis BCG. Table 3.5 summarizes the distribution of mutants according 





H37Rv  CDC  H37Rv  CDC 
QRDR‐A  280  255  88.05  72.64 
QRDR‐B  18  30  5.66  8.54 
Outside‐QRDR‐A  1  16  0.31  4.55 
Outside‐QRDR‐B  8  32  2.51  9.11 
WT DNA gyrase  11  18  3.45  5.12 









FQs selects for alterations mostly on QRDR-A of Mtb strains 
Sequencing of the H37Rv and CDC1551 mutants revealed that 88% and 72% 
respectively had a SNP within the QRDR-A and around 5% and 8% within the 
QRDR-B (Table 3.5). These numbers also correspond to the percentages observed 
in the clinics (Cui et al., 2011). GyrA mutations at 3 positions (G88, A90 and 
D94) alone made up to 96% of the total QRDR-A mutations in both strains (Table 
3.6). Mutants with these SNPs have highest MICs and are considered as the high-
level resistance mutants. Given their high prevalence and impact on drug 
resistance, they are frequently analyzed for the detection of MDR TB. However, 
recent studies indicate that the high-level resistance could also arise from the 
generally overlooked, low level resistant mutants in events when FQ dose is 
inadequate or compromised. In our study ~3.8% of such mutations were observed 
on the QRDR and ~2.8% outside the QRDRs of both the genes (Tables 3.6 and 
3.7). We report here 2 new variants of GyrA recovered from this study; A126E 
and A288D, which exhibited lower MICs (Figure 3.7). 
The QRDR-B region should be redefined 
A significant percentage of mutations were observed outside the QRDRs of both 
the genes. Around 8% H37Rv mutants and 18% CDC1551 mutants had SNPs on 
the GyrB. Amongst these GyrB mutations, the SNPs at T539 and E540 occurred 
in 1/4th and 1/3rd of the total H37Rv and CDC1551 GyrB mutants respectively 
(Table 3.5). Four novel GyrB variants namely T539I, T539A, E540A and S486Y 




GyrA  Mutation H37Rv  CDC  Total 
QRDR‐A  G88C  20  154  174 
A90V  80  68  148 
D94G  102  7  109 
D94H  35  5  40 
D94N  24  4  28 
D94Y  6  4  10 
S91P  3  4  7 
D89N  8  4  12 
D94A  1  2  3 
D94V  1  0  1 
A74S  0  2  2 
S95A  0  1  1 
Outside QRDR‐A  A126E  0  12  12 
A126D  1  0  1 
A288D  0  4  4 










GyrB  Mutation  H37Rv  CDC  Total 
QRDR‐B  N538K  1  19  20 
N538D  10  4  14 
N538S  1  2  3 
N538Y  0  2  2 
N538T  5  0  5 
D500N  0  1  1 
G509S  0  1  1 
L518F  1  1  2 
Outside QRDR‐B  R485C  0  9  9 
T539T  0  5  5 
T539I  1  3  4 
T539A  3  2  5 
E540D  0  3  3 
E540V  2  4  6 
E540A  0  1  1 
S486Y  0  2  2 
S486F  0  2  2 
A543V  2  1  3 
Total  19  26  62  88 
 
[Note: The GyrB numbering system is according to Cole et al. (Cole et al., 1998, 










Predominance of particular gyrase alleles is concentration dependent 
In general, at higher concentrations of FQs, lesser mutants and with high level of 
resistance were selected for both H37Rv and CDC1551 strains (Figure 3.4 and 
3.5). The SNPs at position D94 and G88 were predominantly selected at all FQ 
concentrations in the H37Rv and CDC1551 strains respectively. The SNPs at 
position A90 was predominantly selected at 5 µM and 2 µM of FQs in the H37Rv 
and CDC1551 strains respectively. SNPs in GyrB mostly occurred at lower FQ 







high‐level	 resistance	were	 specifically	 selected	while	 at	 lower	 concentrations	






Figure	 3.5	 Spectrum	 of	 DNA	 gyrase	 alleles	 of	 CDC1551	 selected	 by	
different	concentrations	of	FQs.	At	higher	 concentrations	of	FQs	mutations	
conferring	 high‐level	 resistance	 were	 specifically	 selected	 while	 at	 lower	












3.6.5 Comparison of frequency of mutant types selected at varying FQ 
concentrations 
To analyze the effect of FQ type on the selection of spontaneous mutants we 
separately plotted the spectrum of DNA gyrase alleles selected at varying 
concentrations of each FQ. Figures 3.6 and 3.7 summarize the spectrum of GyrA 
alleles in the FQ resistant H37Rv and CDC1551 strains respectively.  Figures 3.8 
and 3.9 summarize the spectrum of GyrB alleles in the FQ resistant H37Rv and 
CDC1551 strains respectively. 
 
Variants of GyrA in H37Rv and CDC1551 
In the H37Rv strain, D94G was the most abundant SNP selected by all 
concentrations of FQs followed by A90V, several variants of D94 (D94H, D94N, 
D94Y, D94A and D94V) and G88C (Figure 3.6). The aforementioned SNPs were 
also the most predominantly selected SNPs at higher concentrations of all FQs 
(below the concentration where no mutants are selected called MPC; MPC varies 
amongst the FQs) and are associated with high level of resistance. For example, 
only D94 variants (with a few exceptions) were selected at 5 µM of MXF and 
SFX and 20 µM of CIP and OFX.  
In contrast to H37Rv, the most abundant SNP in the CDC1551 strain was G88C 
followed by A90V (Figure 3.7). Nevertheless, similar to H37Rv, they were also 
associated with high level of resistance. Three new SNPs-A74S, A126E and 
A288D were recovered in the CDC1551 strain. All these new variants occurred at 

























GyrA	 alleles	 of	 FQ	 resistant	 CDC1551.	 (The	 digits	 in	 brackets	 indicate	








GyrA	 alleles	 of	 FQ	 resistant	 CDC1551.	 (The	 digits	 in	 brackets	 indicate	




Variants of GyrB in H37Rv and CDC1551 
The GyrB alleles of H37Rv were predominantly selected at lower concentrations 
of all FQs in contrast to GyrA. Yet, within the lower concentration range, the 
high-level resistant GyrB variants were selected at higher concentration.  The 
SNPs at N538 and T539 were more common (Figure 3.8). At 1 µM, MXF and 
SFX selected GyrB alleles that were located outside the QRDR-B. All the five 
H37Rv mutants selected at 2 µM SFX harbored the mutation N538T.  The new 
H37Rv GyrB variants: L518F, T539A and T539I, were found in this study and 
reported for the first time. 
GyrB variations were observed to a greater extent in CDC1551 than in H37Rv. 
The number of distinct GyrB variants in H37Rv and CDC1551 was 9 and 17 
respectively (Table 3.7). Several new variants of GyrB were recovered with the 
CDC1551 strain, namely, R485C, S486Y, G509S, N538Y and E540A in addition 













Figure	 3.8	 Spectrum	 of	 recovered	 H37Rv	 GyrB	 alleles.	 (The	 digits	 in	
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Figure	 3.9	 Spectrum	 of	 recovered	 CDC1551	 GyrB	 alleles.	 (The	 digits	 in	







Figure	 3.9	 Spectrum	 of	 recovered	 CDC1551	 GyrB	 alleles.	 (The	 digits	 in	





3.6.6 Cross resistance- susceptibility of DNA gyrase alleles to FQs 
As mentioned earlier a shift in MIC was observed in M. bovis BCG with the FQ 
resistant mutants in the order GFX < MXF/SFX/CIP < LVX < OFX. Similar trend 
was observed with the DNA gyrase variants of the CDC1551. GFX was the most 
active and exhibited least MICs for all the CDC1551 mutants used in the 
experiment. When the FQ MICs in a few GyrA variants were measured, G88C 
was found to be the least susceptible followed by A90V. The GyrB variants 
N538K and E540V were also less susceptible to the FQs, and thus require higher 
drug concentration to restrict their growth into colonies (Figure 3.10). 
When the MICs FQs in the mutant strains were compared with the wild type 
(WT) CDC1551 strain (Table 3.8), the GyrB mutants with alterations in the non -
QRDR- T539N and R485C showed susceptibility to GFX, MXF and SFX but 
resistance to LVX, CIP and OFX. The GyrA variants with non-QRDR alterations 
exhibited similar MICs as WT. Interestingly, for GyrB variant N538K exhibited 





























































































Figure	 3.10	 Cross	 resistance:	 Susceptibility	 of	 DNA	 gyrase	 variants	 of	
CDC1551	 to	 fluoroquinolones.	 (The	 “n=”	 values	 on	 y‐axis	 of	 GFX	 indicate	




3.6.7 Mutant prevention concentration of FQs 
No mutants were selected above 5 µM of GFX in an inoculum of approximately 
2×1010 CFU (Figure 3.11).  Selection of no mutant could be achieved at 10 µM of 
MXF and SFX and 20 µM of LVX. Whereas, more than 20 µM of CIP and OFX 
was required for limiting the emergence of resistant mutant. MPC for CIP and 
OFX is attainable as shown previously, however experiments with higher than 20 
μM was not possible in our study. 
GFX MPC (5 µM) is below its Cmax (10.15 µM) while both the values for MFX 
are similar (Table 3.8). (Cmax values in pharmacokinetics are defined by the 
maximum concentration a drug can achieve in the given test area of the body). 
Both, CIP and OFX, exhibit very high MPC values while their Cmax is reached at 
lower concentrations. MPCs of CIP and OFX are between 20 µM and 50 µM 































GFX  374.42  400  3.8  33  10.15  5‐10  88.14 
MXF  401.11  400  4.3  36.1  10.72  5‐10  90.00 
SFX  392.41  200  1.1  18.8  2.80  5‐10  47.91 
LVX  361.38  500‐750  6.2  45  17.16  10‐20  124.52
CIP  331.35  250‐750  2.4  11.6  7.24  20‐50  35.01 
OFX  361.38  1000  3  24  8.30  20‐50  66.41 
 
[Note: Cmax- maximum concentration a drug can achieve in the given test area of 
the body 
AUC- Area under the curve or actual body exposure to drug after administration 
of a dose of drug. 













Our results indicate that newer generation FQs namely GFX, MXF and SFX are 
the most potent FQs against Mtb. While, similar potency with CIP, LVX and OFX 
could be achieved only at 4-5 times the concentration of GFX, MXF, and SFX, 
suggesting that these are less potent against Mtb. Secondly, as compared to GFX, 
MXF and SFX, 2 and 4 fold higher concentration of CIP, LVX and SFX was 
required to limit the emergence of M. bovis BCG and Mtb mutants respectively. 
These findings suggest that different generation antibiotics could have different 
frequencies of mutation which is attributed to the potency of the newer generation 
compounds. However, the cross-resistance still remains an issue for drugs from 
the same class of compounds. 
The data presented above also emphasizes that commercially available FQs used 
for treatment of tuberculosis differ with respect to enrichment of resistant 
mutants. The 318 H37Rv and 351 CDC1551 spontaneous mutants obtained in this 
study were analyzed to evaluate the frequency of occurrence of different mutation 
types or gyrase variants by sequencing the target genes- gyrA and gyrB. 
Interestingly only single nucleotide polymorphism were observed unlike the 
occasional double mutations observed in the clinics (Cui et al., 2011). Increasing 
concentrations of the FQs selected for the mutant strains with mutations that 
confer higher-level of resistance and a concentration could be reached where no 
mutant was recovered. This data resonates with the results obtained by Zhou et al. 
with CIP and its analogues. We also observed that, some mutations were 
predominantly selected by a specific FQ, for instance, the newer FQ, MXF, 
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selected most mutants that harbored high-level resistance mutations of gyrA 
(except at lower concentrations) while LVX, CIP and OFX selected wide variety 
of variants on both gyrA and gyrB. Interestingly, selection of variants also 
demonstrated dependence on FQ concentrations, for instance, lower FQ 
concentrations primarily selected variants (low-level resistant mutants) with 
mutations mostly on gyrB and outside of the QRDR-A/B. These results show that, 
the resistance genotype (amino acid mutation in DNA gyrase) and phenotype 
(mutation frequency) depends on the type of FQ as and resonates with the results 
reported by Zhou et al. (Zhou et al., 2000). Interestingly, higher concentration of 
MXF was observed to overcome the low level resistance and corresponds with 
observation reported by Poissy et al. (Poissy et al., 2010).  
Sequencing statistically significant number of mutants allowed us exhaustive 
scrutiny of those low-level resistance mutations that are conventionally ignored, 
owing to the fact that most (85-90%) occur on the hotspot QRDR regions of gyrA 
and gyrB. It is known that, low-level resistance increases probability of clinical 
resistance, and thus, if ignored (in the light of wide use of FQs at lower 
concentrations to treat other infectious diseases) could lead to dire consequences 
(Baquero, 2001). Subsequently, MIC99 determination of the selected mutants 
shows that the level of resistance is often higher than the concentration used for 
selection. This result suggests that appropriate assessment of these mutations in 
TB patients is crucial while the formulation of drug-regimen and has valuable 
contribution towards limiting emergence of resistance.  
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Sequencing the entire gyrA and gyrB gene revealed a significant percent (2.82% 
in H37Rv and 13.66% in CDC1551) of SNPs on the outside of their QRDRs. 
Ignoring these SNPs could cause considerable difference while reporting their 
percentage of mutations on DNA gyrase and probably a hindrance to FQ 
resistance mechanism studies. Moreover, our results support the recent suggestion 
made to include codons 539 and 540 in the QRDR-B (Maruri et al., 2012) taking 
into account that, 25% H37Rv and 33% CDC1551 of GyrB mutations occurred in 
these two codons (current QRDR-B: codon 500-538). Also, mutants with 
alterations at these two codons are known to have higher MIC values and also as 
seen in our cross resistance study (Figure 3.7). 
The cross-resistance patterns exhibited by FQ resistant DNA gyrase variants 
assessed in our study strengthens the argument and significance of understanding 
patient history of FQ usage, prior to the administration of the anti-TB treatment. 
Our results show that the variants selected on one FQ were resistant to all other 
FQs used in this study. Of importance was the differential degree of shift in MIC 
that was observed amongst the FQs in the order of GFX < MXF < SFX < LVX < 
CIP < OFX. GFX and MXF, the newer FQs, had the least shift in MIC which 
reinforced their potency. Interestingly, MIC shift was also observed within the 
variants depending on the type of mutation it harbors; MIC for the G88C variant 
was higher than the D94G and A90V variants of M. bovis BCG and A90V variant 
of CDC1551. The QRDR-B variants N538K and E540Vexhibited increased MIC 
with all the FQs while the non-QRDR-B variants exhibited increased MIC with 
LVX, CIP and OFX. Interestingly, for N538K, the fold increase in MIC with 
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GFX and MXF was higher than OFX. This observation suggests that N538 is 
more susceptible to OFX than GFX or MXF, as reported previously for this GyrB 
variant (Malik et al., 2012) and other GyrB variant N533 (Von Groll et al., 2009) 
reiterates the consideration of analysis of GyrB alterations while investigating the 
FQ resistant clinical isolates. The 2 to 3 fold increase in MIC of the non-QRDR-B 
variants-T539N and E540V emphasize their inclusion in the QRDR-B as 
suggested by Maruri et al. Overall, these MIC values demonstrate their potential 
application in the formulation of drug concentrations in clinical trials. 
The lowest MPC of GFX once again suggests that it is the most potent of all FQs 
followed by MXF and SFX. There seems to be no probability of emergence of 
mutants with GFX, since its MPC is at 5 µM while its Cmax reaches as high as 
10.15 µM at the current GFX dosage. In contrast, CIP and OFX seem to be 
undesirable to limit the emergence of resistant Mtb strains. The MPC experiments 
show that maximum CIP concentration achieved in human body with the current 
dosage is much lower than the concentration required to limit the emergence of 
Mtb resistance. This result support the suggestion made by Field et al. to avoid 
CIP in the TB drug regimen (Field et al., 2012).  In sum, with the currently 
recommended dosages CIP and OFX would certainly lead to resistance, while 
GFX and MXF would prevent resistance. Thus, it is critical to understand the 
MPC of FQ. 
Together, our results suggest consideration of re-designing current FQ 
formulations, re-defining the QRDR region for GyrB and ‘not to’ underestimate 
the significance of low-level resistant mutations. Overall, our study evaluated the 
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determinants necessary to understand the genetics of FQ resistance which would 
be useful in the efforts made to limit the emergence of resistance, thereby aiding 
the TB control program. 
 
3.8 Future	directions	
Cross resistance and MICs were evaluated for only a few DNA gyrase variants. 
Examining these aspects for all the variants and particularly low-level resistant 
mutants would help in better understanding their resistance level. As some of 
these mutations exhibit susceptibility to older FQs but not the more potent newer 
FQs. Such information could be useful in dosing strategies for resistant TB cases. 
Around 3 to 5 percent of the strains had WT DNA gyrase sequencing suggesting 
other mechanisms of FQ resistance, for instance, efflux pumps. Whole genome 
sequencing of these strains would help to acquire this information. 
Although the results obtained here resembles the data observed in the clinics, 














Dormant or non-replicating Mtb harbors in one third of the world population 
which results in latent TB infection (LTBI); 5 – 10% of which, if untreated, has a 
probability to develop active TB infection. Thus, effective diagnosis and 
treatment of LTB infection is one of the goals of the TB control program. As 
mentioned earlier, molecular genetics could also be utilized in the identification of 
novel Mtb drug targets thereby providing insights into the development of new 
class of compounds. As such, 5FU showed antitubercular activity and whole 
genome sequencing of 5-fluorouracil (5FU) resistant mutants led us to the 
identification of uracil phosphoribosyltransferase (MtUPRT) and pyrimidine 
operon regulatory protein (PyrR) as the probable targets in Mtb (Mathys et al., 
unpublished). In the light of its involvement in the energy saving salvage 
pathway, which is possibly active in dormant Mtb, MtUPRT is an attractive Mtb 
target. However, 5FU is highly toxic and cannot be used in TB treatment. 
Nevertheless, structural insights of this protein would help in understanding its 
functional implications in Mtb and facilitate the screening for novel anti-TB 






The enzyme uracil phosphoribosyltransferase (UPRTase; EC 2.4.2.9) which is 
explored as drug target in several clinical conditions (Hughes et al., 2005, Dong 
& Zhang, 2014, Villela et al., 2013, Sunamura et al., 2002, Switzer et al., 1999) is 
involved in the low energy-requiring pyrimidine salvage pathway. As such, it is 
known to be active during the energy-saving seedling (dormant) stage in plants 
(Bressan et al., 1978) and in the absence of de novo pyrimidines in bacteria 
(Martinussen & Hammer, 1994). UPRTases catalyses the conversion of uracil and 
5'-phosphoribosyl-α-1'-pyrophosphate (PRPP) to pyrophosphate (PPi) and uridine 
5’-monophosphate (UMP, the only precursor of all pyrimidine nucleotides) 
(Figure 4.1) (Villela et al., 2011). 
Mechanism of action of 5FU involves formation of toxic metabolites (FUMP- 












Figure	 4.1	 MtUPRT	 function	 in	 salvage	 pathway	 of	 pyrimidine	
biosynthesis	and	probable	action	of	5FU.	MtUPRT	catalyses	the	conversion	
of	 PRPP	 and	 uracil	 to	 UMP	 (the	 precursor	 of	 pyrimidines).	 Uracil	 analogs	
(example,	 5FU)	 disrupt	 this	 MtUPRT	 function	 by	 formation	 of	 FUMP	 and	
cytotoxic	 metabolites	 leading	 to	 cell	 death.	 With	 availability	 of	 MtUPRT	
structure	 and	 the	 target	 based	 drug	 discovery	 approach	 the	 screening	 of	
MtUPRT	inhibitors	would	be	greatly	facilitated.	
[MtUPRT‐	 Mycobacterium	 tuberculosis	 uracil	 phosphoribosyltransferase;	
PRPP‐	 5'‐phosphoribosyl‐α‐1'‐pyrophosphate;	 5FU‐	 5‐fluorouracil;	 UMP‐	








The MtUPRT was indicated as an anti-TB target and probably has activity in the 
LTBI bacteria (Villela et al., 2013). In addition, the anticancer drug 5FU was 
recently shown to target the MtUPRT (Singh et al., 2015). Simultaneously, 
generation of spontaneous mutants against 5FU in our previous study also led to 
identification of mutations in this protein. To validate and access the potential of 
MtUPRT as a target in Mtb it is necessary to determine the structure of MtUPRT. 
Structural insights into the interactions of 5FU with MtUPRT would aid in 
synthesizing 5FU analogues with minimal toxicity. 
4.3 Objectives	
The objectives for this part of the study were firstly to elucidate the crystal 
structure of Mtb UPRT (MtUPRT) and MtUPRT in complex with 5FU to 
understand their interactions. Secondly, to establish the correlation between the 
spontaneous mutational sites of MtUPRT (selected in the presence of 5FU) and 





The upp gene was cloned and overexpressed in BL21E. coli to yield the 
recombinant MtUPRT protein. The protein was purified to homogeneity in three 
step purification by chromatography. The 27.4 kDa MtUPRT eluted in tetrameric 
form at a volume corresponding to 120 kDa (Figure 4.2). In addition, the 
Dynamic Light Scattering (DLS) measurements confirmed the protein to be in a 





















Figure	 4.2(a)	Gel‐filtration	 chromatography	 elution	 profiles	 of	MtUPRT	
and	 the	 protein	 standard.	MtUPRT	 and	 the	 protein	 standard	were	 eluted	
from	an	analytical	column	(Superdex	200	10/300	GL).	The	MtUPRT	eluted	at	
12.8	 ml,	 which	 is	 consistent	 with	 a	 tetrameric	 association	 in	 solution	 as	
observed	in	DLS	data.	
(b)	The	purity	of	MtUPRT	(27.4	kDa)	characterized	by	4–12%	SDS‐PAGE.	
The	 gel	 was	 stained	 followed	 by	 Coomassie	 staining.	 Lane	 1	 contains	 the	















[Note:	The	polydispersity	 index	 (PolydIndx)	values	 smaller	 than	0.05	 indicate	











The structure of MtUPRT was solved by molecular replacement method and 
refined up to 3Å resolution (Table 4.1, PDB code: 5E38) (Ghode et al., 2015). 
The MtUPRT molecule consists of a β-sheet sandwiched by 6 α-helices (including 
2 single-turn helices). In all the monomers, a part of the β-arm region (Arg55-
Ser64) had no interpretable electron density and were not modeled. There are four 
molecules in the asymmetric unit (Figure 4.5) and are consistent with the in 
solution studies. 
A sequence homology search of the GenBank/EMBL/DDBJ database for 
MtUPRT was conducted using BLAST (Altschul et al., 1990). The result showed 
that MtUPRT sequence is highly conserved in bacterial species. Although the 
gene encoding UPRTase is present in human, it does not have any detectable 
activity (Schumacher et al., 1998). Also, the MtUPRT protein sequence alignment 
with its human analogue shows no consensus and hence might prove to be an 
attractive target in Mtb. (Figure 4.4). MtUPRT and its homologs share a highly 
conserved PRPP binding 12-residue sequence and the uracil binding residues 
(Schumacher et al., 1998). A search for structurally similar proteins within the 
PDB database was performed using the DALI server (Holm & Rosenstrom, 2010) 
which revealed several structurally similar proteins that includes UPRTases from 
bacteria with a sequence identity ranging from 48% to 37% and RMSD of less 
than 2.1Å. These structural similarities indicate that, despite being from various 
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species with varying sequence identity, the structures of the UPRTases are similar 
and conserved. 
MtUPRT is a dimer of dimer similar to several of its homologs (Figure 4.5). The 
four molecules of the asymmetric unit are identical with an RMSD less than 1Å 
for the pairwise comparison of Cα atoms. The total buried area of a monomer in 
the asymmetric unit is approximately1600Å2. There are nine hydrogen bonding 
contacts between the monomers of the tetramer, besides the several hydrophobic 
interactions. 
In order to understand the substrate specificity, we briefly attempted to crystallize 
MtUPRT along with uracil and 5FU. However, no interpretable density was 
observed for these ligands. This led us to model the ligand-MtUPRT complex 
using the UMP-UPRT homolog complex structure from Thermotoga maritime 
(PDB code 1O5O). The superposition of homolog complex onto MtUPRT 
inferred the UMP binding pocket of MtUPRT. The UMP binding pocket of 
MtUPRT consists of Arg102, Met131, Thr134, Gly135, Ser137, Tyr191 and 
Asp198 (Figure 4.6). Out of the four spontaneous mutational sites identified and 
mapped on the MtUPRT structure (discussed in section 4.4.3), two were 























aData for the highest resolution bin is in parentheses. 
bRmerge = Σ|Ii − Im|/ΣIi, where Ii is the intensity of the measured reflection and Im is 
the mean intensity of all symmetry-related reflections. 
cRwork = Σ| |Fobs| − |Fcalc| |/Σ|Fobs|, where Fobs and Fcalc are observed and 
calculated structure factors, respectively. Rfree = ΣT| |Fobs| − |Fcalc| |/ΣT|Fobs|, where 
T denotes a test data set of about 5% of the total reflections randomly chosen and set 
aside prior to refinement. 






Figure	 4.4	Multiple	 sequence	 alignment	 between	 human	 and	 bacterial	
UPRTases.	 The	 identical	 conserved	 residues	 are	 indicated	 by	 stars.	 The	 highly	
conserved	 PRPP	 binding	 domain	 is	 marked	 in	 red	 box	 (Villela	 et	 al.,	 2013).	 The	
residues	 implicated	 for	 uracil	 binding	 in	 B.	 caldolyticus	 are	 shown	 in	 black	 box	







Figure	 4.5	 Structure	 of	MtUPRT	 tetramer	 in	 an	 asymmetric	 unit	 of	 the	
crystal. Each monomer is shown in different color. (The N and C terminals of the 










To understand the implication of MtUPRT in the 5FU resistance, we selected 
spontaneous mutants with 5 and 20 µg/ml 5-FU (12 and 25 times the MIC90 
respectively) using the M. bovis BCG strain. MtUPRT encoding upp gene was 
sequenced for 42 independent isolates, eight of which contained polymorphisms 
on upp (Table 4.2). Here, we report four distinct single nucleotide polymorphisms 
(SNPs) and two distinct deletions (2 mutants contained the same deletion) that 
were observed in the upp gene of the 5FU resistant mutants for the first time. The 
four SNPs resulted in mutated residues namely Arg45Pro, Gly63Arg, Gly81Val 
and Cys157Tyr which were mapped on the MtUPRT structure (Figure 4.6). The 
closest of them, Cys157Tyr is at a distance of approximately 10Å from the UMP. 



















Arg45Pro  g134c  5  1 
Gly63Arg  g187c  20  1 
Gly81Val  g470a  5  1 
Cys157Tyr   g242t  20  1 
Nucleotide deletions/ Frameshift 
Leu32Cys  c94 deleted  5  1 
Tyr105Pro  a316 deleted  5 (2), 20 (1)  3 






























The susceptibility of the 5FU mutants was compared against wild type M. bovis 
BCG by evaluating the MIC50 of the strains. A decrease in susceptibility from 5- 
to 20- fold was observed in the mutant strains. The mutant Gly63Arg showed the 
least susceptibility to 5FU with 20-fold increase in MIC50, followed by 





resistant	 mutants.	 Gly63Arg	 exhibits	 the	 highest	 increase	 in	 MIC50.	 MIC50	







No new class of chemical compounds have been developed for 4 decades in the 
TB drug regimen after the introduction of quinolones in the 1960’s (Walsh, 
2003b). New therapeutics which can offer shorter treatment duration and 
compatibility with HIV drugs are an immediate requirement to achieve the long 
term targets of the TB control program. Thus, identifying and validating new 
targets for developing new drugs, is of utmost priority for TB treatment and to 
control the emergence of resistance (WHO, 2013).  
MtUPRT was recently identified as a target of the anti-cancer drug, 5FU.  Given 
that 5FU is a pyrimidine/ uracil analog, it possibly interacts directly with 
MtUPRT as observed in other bacterial species (Schumacher et al., 1998). 5FU is 
also known to inhibit growth in several bacteria, for example, P. aeruginosa and 
E. coli (Attila et al., 2009, Imperi et al., 2013, Rangel-Vega et al., 2015). The 
mechanism of action of 5FU in Mtb was recently studied by Singh et al., where 
5FU resistance in Mtb was attributed to the mutations in the genes upp and pyrR 
(pyrimidine operon regulatory protein) (Singh et al., 2015). In their study, 
generation of spontaneous mutants against 5FU (at 5 times MIC90) resulted in 3 
out of 10 mutants with a nucleotide deletion at position 74 in the upp gene. Using 
a similar approach, we isolated 48 mutant Mtb colonies selected against 5FU and 
sequenced for the upp gene. In our study, 6 novel upp alterations in 8 independent 
5FU resistant isolates (3 isolates had the same mutation) were identified. The 
remaining mutants with wild type upp sequence suggest additional targets or 
mechanisms of 5FU resistance; for example the pyrimidine operon regulatory 
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protein (PyrR) as indicated by Singh et al., and as discussed in chapter 5. In this 
study, we report the crystal structure of MtUPRT for the first time along with 
mapping of the novel spontaneous mutational sites of MtUPRT obtained in this 
study.    
Although the four mutational sites identified were located away from the 
proposed MtUPRT catalytic or uracil binding site, three of them (Arg45, Gly63 
and Gly81) were either conserved in other bacterial species or belonged to the 
same amino acid group (Non-polar, aliphatic). This observation implies the 
probable role of these sites in resistance mechanism or function of the protein. 
Nonetheless, in the light of its involvement in energy saving salvage pathway, 
MtUPRT is an attractive dormant Mtb target. The structural and functional 
insights of MtUPRT would aid in validation of this novel TB target. Screening for 
the inhibitors, in a structure activity relationship approach, would greatly 
accelerate the development of novel anti-TB therapeutics and strategies. 
 
4.6 Future directions 
The four mutations that occurred on MtUPRT on exposure to 5FU were located 
away from the 5FU binding site implicating they may have minimal or no impact 
on the interaction. To address this hypothesis, effect of 5FU interaction on the 
mutated MtUPRT protein activity will be assessed, using the site directed 









The ability of Mtb to enter into a persistent stage in the host without disease 
symptoms is fundamental to the pathogenic success of Mtb (Gengenbacher & 
Kaufmann, 2012). Thus, the development of new drugs with novel mechanisms of 
actions, that can address the above issues, is urgently needed (O'Brien & Nunn, 
2001). As mentioned earlier, antitubercular activity was demonstrated by 
Tsukamura et al. in 1979. 5FU also exhibited antitubercular activity in Mtb-
H37Rv strain in our experiments, exhibiting dose dependent inhibition. The 
mechanism of resistance of 5FU in Mtb was studied only recently by Singh et al., 
where 5FU resistance in Mtb was attributed to the mutations in the genes upp and 
pyrR encoding the ezymes MtUPRT and pyrimidine operon regulatory protein 
(PyrR) respectively (Singh et al., 2015). Structural insights of these proteins 
would help in understanding its functional implications in Mtb and facilitate the 
screening for novel anti-TB chemical entities.  
5.1 Role of PyrR in pyrimidine biosynthesis 
The gene encoding Mtb PyrR is located on the pyr operon along with the enzymes 
involved in the de novo pyrimidine biosynthesis pathway. PyrR regulates the 
above enzymes resulting in transcription termination (Cole et al., 1998). PyrR 
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executes this function by binding to the pyr operon mRNA (conserved sequence) 
thereby disrupting the antiterminator. In addition to its regulatory function, PyrR 
is also known to have residual uracil phosphoribosyltransferase (UPRTase) 
activity. The UPRTase activity involves conversion of the substrates uracil and 5'-
phosphoribosyl-α-1'-pyrophosphate (PRPP) to uridine 5’-monophosphate (UMP) 
and pyrophosphate (PPi) (Villela et al., 2011). This UPRTase function was 
recently implicated to be disrupted by an anticancer drug 5FU (an uracil 
analogue) making PyrR an attractive target in Mtb.  
5.2 PyrR as a potential target in Mtb 
Antitubercular activity of 5FU is known since 1979, however, it was not pursued 
as a potential TB drug given the toxic side effects of 5FU. Nonetheless, 5FU can 
be chemically modified in a target based drug discovery approach (Duncan, 
2004), provided structural insights into 5FU interactions with PyrR are available. 
To that end, we solved the co-crystal structure of Mtb PyrR-5FU complex for the 
first time. To establish the plausible interactions between PyrR residues and 5FU 
deduced from the previous study, we selected spontaneous mutants in the 
presence of 5FU. Sequencing the pyrR gene of these mutants led us to the 
identification of thirteen mutational sites of Mtb PyrR, four of which were located 
in close proximity to 5FU binding site. The knowledge on the PyrR-5FU complex 
structure will aid in the screening of Mtb PyrR inhibitors and will assist in design 





The objectives for this part of the study were firstly, to elucidate the co-crystal 
structure of Mtb PyrR in complex with 5FU to understand the interactions of 5FU 
with PyrR. Secondly, to establish the correlation between the spontaneous 
mutational sites of PyrR and 5FU resistance mechanism. 
5.4 Results 
5.4.1 Mtb PyrR purification and characterization 
The pyrR gene cloned in pET28b was overexpressed in E. coli to yield the 
recombinant Mtb PyrR protein. The protein was purified to homogeneity in two 
step purification by chromatography. The 22.6 kDa PyrR eluted in monomeric 
form at a volume corresponding to <25 kDa on a HiLoad 16/60 S200 gel filtration 
column. The DLS experiment carried out after protein concentration (4 mg/ml) 
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5.4.2 Structure of Mtb PyrR  
The structure of Mtb PyrR was solved by molecular replacement method using 
PDB 1W30 as a search model and refined up to 2.6 Å resolution (Table 5.1,PDB 
code: 5IAO) (Ghode et al., 2016). The pyrR molecule consists of an antiparallel 
β-sheet with three β-strands and a parallel β-sheet with four β-strands along with 
four α-helices (including a single-turn helix). The amino acid residues 91-101 had 
no interpretable electron density and were not modeled.  There are six molecules 
(trimer of dimers) in the asymmetric unit (Figure 5.4). The dynamic light 
scattering experiments indicated the presence of hexamer in the concentrated 
protein solution consistent with the crystal structure observation.  The six 
molecules of the asymmetric unit are identical with an RMSD less than 1Å for the 
pairwise comparison of Cα atoms.  The total buried area of a monomer in the 
asymmetric unit is approximately 1500Å2.  There are ten hydrogen bonding 
contacts between the monomers, besides several hydrophobic interactions. 
A simulated annealing map for the 5FU residue is shown in Figure 5.5. The 5FU 
molecule is found to form hydrogen bonds with Arg58, His177 and Arg179. 
Furthermore, a water molecule is found to stabilize the 5FU interaction by 
forming hydrogen bonds with an oxygen atom from 5FU and Asp120. 
A search for structurally similar proteins within the PDB database was performed 
using the DALI server (Holm & Rosenstrom, 2010) which revealed several 
structurally similar proteins ranging from RMSD 1.1 to 3.3 (sequence identity 
from 58 to 18%) in the first 100 hits. The closest homologs includes, Bacillus 
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caldolyticus with RMSD of 1.1 (55% sequence identity) followed by PyrR from 
Bacillus subtilis with RMSD of 1.3 (53% sequence identity). 
A sequence homology search of the GenBank/EMBL/DDBJ database for Mtb 
PyrR was conducted using BLAST (Altschul et al., 1990). The result showed that 
PyrR homologues are present over the archaea and bacterial species. The closest 
homologs of Mtb PyrR are from other mycobacterial species and are highly 
conserved. The sequence alignment of Mtb PyrR with its homologs is shown in 
Figure 5.3. The figure also indicates the conserved regions of PRPP and uracil as 
observed in other species. The UPRTases from other species are also aligned with 
PyrR to indicate the conserved residues essential for the UPRTase activity in both 
the enzymes. Amongst the PyrR homologs, the PyrR mutational sites were either 













Figure	5.3	Multiple	 sequence	alignment	of	Mtb	PyrR	with	 its	 structural	
homologues	 and	 UPRTases	 across	 the	 bacterial	 species.	 Sites	 of	
spontaneous	mutations	 in	 PyrR	 from	Mtb	 are	 indicated	 by	 an	 asterisk.	 The	
residues	 involved	 in	 PRPP	 binding	 are	 highlighted	 by	 a	 black	 box.	 Val178,	
which	is	observed	to	be	involved	in	water‐mediated	hydrogen	bonding	contact	













Figure	 5.4	 Cartoon	 representation	 of	 the	 Mtb	 PyrR‐5FU	 complex.	 The	
crystal	 shows	 hexameric	 association	 of	 the	 six	 PyrR	 monomers	 in	 one	











Figure	 5.5	 Simulated	 annealing	 omit	 map	 of	 the	 5‐fluorouracil	 (5FU)	

















study	 are	 highlighted	 in	 pink.	 Mutations	 observed	 by	 Singh	 et	 al.	 are	












Figure	 5.6(b)	 Molecular	 surface	 representation	 of	 PyrR‐5FU	 complex	
structure	along	with	mapping	of	mutational	 sites.	This	 figure	 is	 in	 same	




























aData for the highest resolution bin is in parentheses. 
bRmerge= Σ|Ii − Im|/ΣIi, where Ii is the intensity of the measured reflection and Im is the 
mean intensity of all symmetry-related reflections. 
cRwork= Σ| |Fobs| − |Fcalc| |/Σ|Fobs|, where Fobs and Fcalc are observed and 
calculated structure factors, respectively. Rfree = ΣT| |Fobs| − |Fcalc| |/ΣT|Fobs|, where 
T denotes a test data set of about 4% of the total reflections randomly chosen and set 
aside prior to refinement. 





5.4.3 Mapping of spontaneous mutations that confer 5FU resistance in Mtb, 
on the PyrR structure 
Mtb PyrR was recently reinvestigated as potential target of an anti-cancer drug 5-
fluorouracil (5FU) (Singh et al., 2015). To understand the implication of Mtb 
PyrR in the 5FU resistance, we selected for spontaneous mutants with 5 µg/ml 
and 20 µg/ml 5-FU (12 and 25 times the MIC90 respectively). Mtb PyrR encoding 
pyrR gene was sequenced for 45 independent isolates, 20 of which contained 
polymorphisms on the pyrR gene. Amongst these 20 mutants, 13 harbour distinct 
single nucleotide polymorphisms (SNPs) in the pyrR gene, 12 of which are novel 
(Table 5.2). We also identified 2 distinct nucleotide insertions and 3 distinct 
deletions of nucleotide(s) resulting in frameshift (Table 5.2). We mapped the 
above spontaneous mutational sites or residues on the PyrR-5FU complex 
structure to understand their implications in 5FU resistance, if any. Apart from the 
mutations obtained from our study, we also mapped the mutations observed by 
Singh et al. onto our structure. Further, we modeled the PRPP binding site by 
aligning the PDB structure 1I14. The RMSD for the alignment was observed to be 
0.94. Among the 12 mutational sites mapped  Val178 lie in close proximity to the 
5FU binding site, whereas  the residues Gly54, Pro56, Asp119, Arg126 and 
Ser127 were observed to be close to the binding site of modeled PRPP (Figure 
5.6). The spontaneous mutations reported by Singh et al., Leu62 and Leu180, 







The susceptibility of the 5FU mutants was compared against wild type M. bovis 
BCG by evaluating the MIC50 of the strains. The MIC50 values for the 5-FU 
mutants revealed a decrease in their susceptibility to 5-FU; particularly the strain 
bearing a mutation at the 5-FU binding site, Val178, which exhibited a 60-fold 
decrease. Strains with mutations in the PRPP binding sites, Asp119 and Ser127, 
























Gly54Arg  g160c  20  1 
Pro56Ser  c166t  20  1 
Thr86Ala  a256g  5  2 
Thr86Pro  a256c  20  1 
Asp90Glu  c270g  5  1 
Asp90Asn  g268a  20  1 
Ala101Pro  g301c  20  1 
Asp119Gly  a356g  20  1 
Arg126Cys  c376t  5  1 
Ser127Leu  c380t  20  1 
Ser127Pro  t379c  20  1 
Pro158Arg  c473g  20  1 











5.5  Discussion 
TB drug pipeline has been stagnant until recently as opposed to the rapidly 
evolving resistant Mtb, the causative agent of TB (Ramaswamy & Musser, 1998). 
No new class of chemical compounds have been developed in the TB drug 
regimen after the introduction of quinolones in the 1960’s (Walsh, 2003b) until 
the introduction of linezolid. The most effective drugs in the current TB drug 
regimen are decades old and are ineffective against the resistant Mtb. The 
emergence of resistance is attributed to the ability of Mtb to enter a persistent 
stage which is difficult to eradicate with the available TB drugs. Thus, identifying 
and validating new targets for developing new drugs (novel mechanism of action) 
is of utmost priority for TB treatment and control of resistance (WHO, 2013). 
Identification of active proteins in the essential yet, less explored biological 
pathways in Mtb persistence holds promise in identification of novel drug targets. 
Correspondingly, several pathways (enzymes) have been indicated to be essential 
for Mtb in the persistence (Wayne & Lin, 1982, Sherman et al., 2001). 
One such investigational pathway is the pyrimidine biosynthesis pathway. The 
pyrimidine biosynthesis mechanisms differ in mammals and bacteria making it an 
attractive pathway to explore for potential targets in Mtb (Kantardjieff et al., 
2005). The regulatory enzyme, PyrR, from this pathway was recently identified as 
a target of an anti-cancer drug, 5FU. The anti-mycobacterial activity of 5FU was 
demonstrated more than 3 decades ago (Tsukamura, 1979), however, its 
investigation as a potential TB drug had not been pursued until recently.  The 
mechanism of action of 5FU in Mtb was studied by Singh et al., where 5FU 
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resistance in Mtb was attributed to the mutations in the genes upp and pyrR (Singh 
et al., 2015). However, PyrR-5FU interactions are not known yet In this study the 
crystal structure of Mtb PyrR in complex with 5FU is reported for the first time. 
In addition we also mapped the novel spontaneous mutational sites obtained from 
our study and from Singh et al. on the Mtb PyrR structure to understand their 
functional implications in 5FU resistance. 
We identified 12 novel amino acid residue changes in 15 independent 5FU 
resistant isolates, in addition to one previously reported mutation (Arg126Cys) 
(Singh et al., 2015). Besides, we also observed 5 mutants with deletions or 
insertions of single or a few nucleotides, re-instating the availability of an 
alternative UPRTase in Mtb (Table 2). The remaining mutants with wild type 
pyrR sequence suggest additional targets or mechanisms of 5FU resistance; for 
example the Mtb uracil phosphoribosyltransferase (MtUPRT) as indicated by 
Singh et al. and in our earlier study (Ghode et al., 2015). 
The mutational sites, Arg58, Asp120, His177, Val178 and Arg179 lie in close 
proximity to the 5FU binding site. Notably, a water molecule is observed to 
stabilize 5-FU interaction with PyrR. This water molecule mediates hydrogen 
bonding interaction between oxygen atom of 5-FU with Asp120 side chain and 
Val178 amine. Furthermore the residues Asp119, Gly125, Arg126 and Ser127 are 
observed to be close to the binding site of modeled PRPP. Notably, the UPRTase 
activity of PyrR is not critical for the survival of the Mtb and hence a mutation 
that could hinder the binding of PRPP would also result in blocking the 
production of toxic FUMP. The 5FU susceptibility results (increased MICs of the 
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mutants) also indicate the possible interactions of these sites with the substrates 
Uracil, 5FU and PRPP. Together these observations imply the probable roles of 
Uracil/ 5FU- and PRPP- binding site mutations in the 5FU resistance mechanism 
in Mtb. 
5.6  Future directions 
The role of the residues: Leu62, Val178 and Leu180, which lie in close proximity 
to the 5FU binding site of the PyrR, will be validated by site-directed mutagenesis 
followed by ITC and activity assays. Mapping of PyrR mutations on the PyrR-
UMP structure revealed that most of the mutations were located in the PRPP 
binding site of the protein (Pro56, Asp119, Gly125, Arg126 and Ser127). 
Implications of these sites in the 5FU mechanism of action will be studied in the 













Fluoroquinolones are used in the treatment of resistant TB. It is essential to 
understand the molecular genetics of FQ resistance before its clinical significance 
is challenged. As such, our study should give a snapshot of molecular genetics of 
resistance of the major FQs that are involved in the infectious diseases drug 
regimens including TB. Newer generation FQs, gatifloxacin (GFX), moxifloxacin 
(MXF) and sparfloxacin (SFX) were the most potent FQs against Mtb. Secondly, 
as compared to GFX, MXF and SFX, 2 and 4 fold higher concentration of 
ciprofloxacin (CIP), levofloxacin (LVX) and ofloxacin (OFX) was required to 
limit the emergence of M. bovis BCG and Mtb mutants respectively. These 
findings suggests that different generation antibiotics from the same class of 
compounds have different frequencies of mutation, which is attributed to the 
better structural modifications in newer generation molecules. 
The evaluation of the mutation frequency and mutation type selected by different 
fluoroquinolones at varying concentrations in a single experimental setup should 
help in formulation of drug regimens. With increasing concentrations of the FQs, 
the mutant strains with mutations that confer higher-level of resistance were 
selected until a concentration reached beyond which no mutant was recovered. 
Lower FQ concentrations primarily selected variants (low-level resistance 
mutants) with mutations mostly on gyrB and outside of the QRDR-A/B. Some 
mutations were predominantly selected by a specific FQ while LVX and OFX 
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selected wide variety of variants on both gyrA and gyrB. Our results resonates the 
phenomenon that, the resistance genotype (amino acid mutation in DNA gyrase) 
and phenotype (mutation frequency) depends on the type of FQ (Zhou et al., 
2000). 
The evaluation of resistance levels conferred by the generally unnoticed mutations 
should help in designing better resistance diagnostics tools. It is known that low-
level resistance increases probability of clinical resistance and thus, in the light of 
wide use of FQ at lower concentrations to treat other infectious diseases, if 
ignored could lead to dire consequences (Baquero, 2001). Correspondingly, some 
rare and low-level resistance mutants recovered during our study show increased 
MIC to FQs, suggesting that appropriate assessment of these mutations in TB 
patients is crucial while deciding the drug-regime and has valuable contribution 
towards limiting emergence of resistance.  
The cross-resistance patterns exhibited by FQ resistant DNA gyrase variants in 
our study strengthen the argument and significance of understanding patient 
history of FQ usage prior to beginning of the anti-TB treatment. The differential 
degree of shift in MIC was observed amongst the FQs in the order of GFX < 
MXF/SFX/CIP < LVX < OFX. These MIC values show their potential 
application in the formulation of drug concentrations in clinical trials. In addition, 
the results obtained in the cross-resistance studies reinforced the potency of GFX 
and MXF, the newer generation of FQs. 
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The MPC experiments carried out in our study have further established better 
grounds for rational formulation of anti-TB drug regimen. Our FQ MPC results 
suggest that, GFX with its Cmax higher than its MPC is promising to limit the 
emergence of resistant mutants, while the currently used CIP dosage is 
insufficient to restrict mutants. These results, therefore suggest consideration of 
re-designing current FQ formulations for both older and newer FQs which would 
aid in the TB control program. 
The emergence of resistant Mtb infection and the dearth of newer class of anti-
tuberculous drugs have made identification and validation of novel targets and 
drugs imperative. Most of the current drugs have the limitation of cross resistance 
or inability to target the latent stage of TB. Combination therapy in TB treatment 
is the key to control the emergence of drug resistance. Thus, availability of novel 
targets in Mtb that offer distinct mechanism of resistance would be of great help 
in the efforts to eradicate TB. The two essential enzymes in the pyrimidine 
biosynthesis pathway, MtUPRT and PyrR, were recently indicated to be involved 
in the mechanism of 5-fluorouracil (5FU) action and resistance in Mtb. 
Consequently, our study on the structural and functional insights of MtUPRT and 
PyrR, to elucidate the interactions between these two enzymes and 5FU are 
essential for understanding its implications in TB. The structure determination 
and mapping of spontaneous mutations on the MtUPRT revealed residues located 
away from the substrate binding site. This result suggest that, taking into account 
the activity of MtUPRT in the low energy requiring salvage pathway, aerobically 
generating the spontaneous mutants could have hampered the exact selection of 
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the mutational sites. Nonetheless, MtUPRT is known to be active in the dormant 
Mtb and hence an attractive target to screen for potent inhibitors that would help 
in the treatment of latent TB infection. 
The structure determination and mapping of spontaneous mutations on the PyrR 
revealed that most residues located in the PRPP or UMP binding site of the 
enzyme, suggesting that Mtb overcomes the drug action by mutating both the 
substrate binding sites thereby inhibiting the production of toxic metabolites. 
Interestingly, the frameshift and deletion mutations in both the enzymes suggest 
the redundancy and availability of functionally similar enzymes in Mtb.  
In the light of pyrimidine analogs are considered to inhibit these enzymes in other 
bacterial models, the present structural insights into the enzymes and the 
mutational sites will aid in the screening of appropriate inhibitors and thus assist 
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